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Summary 
After tuberculosis and leprosy, Buruli ulcer (BU) which is caused by Mycobacterium 
ulcerans, is the most common mycobacterial infection in immuno-competent humans. 
Since the 1980s BU has gained significant public health importance in the tropics 
especially in West Africa, including Ghana. The establishment of control measures is 
hampered as a result of the scarcity of understanding of many features of the disease. 
Priority areas for research defined by WHO include: understanding the mode of 
transmission, development of simpler methods for early diagnosis, development of 
effective antibiotic treatment, and the understanding of protective immune responses to 
support vaccine development. 
The availability of M. ulcerans isolates from endemic areas is necessary for detailed 
transmission studies and the analysis of efficacy of antibiotics for the treatment of BU. 
However, cultivation of M. ulcerans from clinical specimens is burdensome; reported 
recovery rates are as low as 20%. We evaluated four different decontamination methods 
and one non-decontamination procedure in combination with four egg-based media for 
the primary isolation of M. ulcerans from tissue specimens excised from BU lesions. 
Oxalic acid decontamination and culture on LJ medium supplemented with glycerol was 
the most efficient procedure and achieved a recovery rate of 75.6%. The success of 
cultivation depended also on a good sampling procedure. The use of the optimised 
cultivation method has allowed the production of a large isolate collection.  
For efficient case management and confirmation of epidemiological data, it is necessary 
to reconfirm clinical diagnosis by laboratory procedures. We used culture together with 
PCR and direct AFB staining to establish a system of reconfirming cases clinically 
diagnosed at the Amasaman Health Centre, Ghana. All three methods showed a 
comparable sensitivity and the laboratory analysis demonstrated a high accuracy of 
clinical judgment by an experienced clinician.  
Current recommendation by the WHO requires that BU patients be treated with a 
combination of rifampicin and streptomycin for 8 weeks before surgical excision. In 
many infectious diseases, the development of drug resistance has a serious impact on 
patient management. It is therefore essential to monitor the drug susceptibility of M. 
ulcerans. We analysed the susceptibility of 28 isolates to rifampicin, streptomycin 
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isoniazid and ethambutol and identified both streptomycin and rifampicin resistant strains 
in Ghana. Findings from this study call for reconsideration of the current treatment 
guidelines.  
Currently, micro-epidemiological studies aiming to reveal transmission chains cannot be 
done in BU. This is due to the low degree of genetic polymorphism in M. ulcerans 
revealed by routinely used genetic fingerprinting procedures. We used VNTR typing 
based on a newly identified polymorphic locus designated ST1 and the previously 
described locus MIRU 1 to detect genetic diversity in isolates from Ghana. Analysis 
revealed three different genotypes in isolates from Ghana, demonstrating for the first time 
genetic diversity among M. ulcerans isolates in an African country.  
Ex vivo ELISpot analysis of IFN-γ secreting cells was carried out by stimulating PBMCs 
from BU patients with PPD, IPP and IRIV. Data from the study demonstrated for the first 
time that M. ulcerans infection-associated systemic reduction in IFN-γ responses is not 
confined to stimulation with live or dead mycobacteria and their products but extends to 
other antigens. We also showed that the immune suppression reversed after surgical 
treatment and that the suppression is not related to reduction in IL-12 secretions. This 
indicates that the observed systemic immunosuppression was not the consequence of a 
genetic defect in T cell function predisposing for BU but is rather related to the presence 
of M. ulcerans bacteria. 
In a longitudinal study, we compared recovery of immediate effector function of Vγ2Vδ2 
T cells in surgically treated BU patients to that of TB patients under chemotherapy. At 
the time of diagnosis, systemic production of IFN-γ after IPP stimulation was suppressed 
in both disease states but reverses after treatment. Restoration of Vγ2Vδ2 reactivity was 
slow such that an optimum response was not yet achieved by two months in both 
populations. Our result demonstrates that immunosuppression in BU may not be caused 
by the terpenoid toxin of M. ulcerans (mycolactone) alone. 
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Zusammenfassung 
Nach Tuberkulose und Lepra ist Buruli Ulkus (BU), verursacht durch Mycobacterium 
ulcerans, die häufigste mycobakterielle Infektion bei immunkompetenten Menschen. In 
den letzten dreissig Jahren hat BU in den Tropen, insbesondere in West Afrika, 
einschliesslich Ghana, an Bedeutung gewonnen. Die effiziente Kontrolle diser Infektion 
ist durch fehlendes Verständnis vieler Aspekte der Krankheit erschwert. Die von der 
WHO aufgestellten Forschungsprioritäten beinhalten: Übertragungswege zu verstehen, 
einfachere Methoden für eine Frühdiagnostik und eine effektive Antibiotikabehandlung 
zu entwickeln und für eine Imfstoffentwicklung zu einem besseren Verständnis der 
schützenden Immunantworten zu kommen.  
Die Etablierung einer Sammlung von M. ulcerans Isolaten aus endemischen Gebieten ist 
für detaillierte Transmissionstudien und die Analyse der Effektivität von Antibiotika 
gegen M. ulcerans erforderlich. Die Kultivation von M. ulcerans ist langwierig und 
beschrieben Ausbeuten liegen teilweise unter 20%. Für die Primär-Isolation von M. 
ulcerans aus Gewebeproben von BU Läsionen evaluierten wir vier Dekontaminations-
Methoden und ein Nicht-Dekontaminations Verfahren mit vier Medien auf Ei-Basis. 
Oxalsäure-Dekontamination und Kultivation auf LJ Medium mit Zusatz von Glycerin 
war das effektivste Verfahren mit einer Aubeute von 75.6%. Der Erfolg der Kultivation 
hing jedoch auch von einer guten Probennahme ab. Die Verwendung eines optimierten 
Kultivationsprotokolls emöglichte uns den Aufbau einer grossen Probensammlung.  
Für effizientes Patientenmanagement und die Bestätigung epidemiologischer Daten ist 
eine Rückbestätigung der klinischen Diagnose durch Labormethoden unerlässlich. Für 
die Etablierung einer Routine-Labordiagnostik der Fälle, die im Amasaman Health 
Center in Ghana klinisch diagnostiziert wurden, setzten wir die Kultivation zusammen 
mit einer PCR-Analyse und direkter AFB Färbung der Mycobakterien ein. Alle drei 
Methoden zeigten vergleichbare Senstitvität. Ferner erwies sich die durch einen 
erfahrenen Kliniker durchgeführte klinische Diagnose als sehr zuverlässig.  
Derzeitige empfiehlt die WHO zur Behandlung von BU eine achtwöchige 
Antibiotikatherapie mit einer Kombination aus Rifampicin und Streptomycin mit 
eventuell nachfolgender chirurgischer Entfernung der Läsionen. Bei vielen 
Infektionskrankheiten hat Antibiotikaresistenz ernsthafte negative Konsequenzen für die 
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therapeutischen Optionen. Es ist somit unerlässlich, die potentielle Entwicklung von 
Antibiotikaresistenzen bei M. ulcerans zu überwachen. Wir analysierten 28 Isolate aus 
Ghana auf ihre Empfindlichkeit gegenüber Rifampicin, Streptomycin, Isoniazid und 
Ethambutol und identifizierten sowohl Streptomycin-, als auch Rifampicin- resistente 
Stämme. Die Resultate dieser Studie sprechen dafür, die derzeitigen 
Behandlungsrichtlinies zu überdenken.  
Molekular-epidemiologische Studien zur Identfizierung möglicher Übertragungswege 
sind im Fall von BU wegen des geringen genetischen Polymorphismus des Erregers und 
der daraus resultierenden geringen Auflösungskraft der gängigen 
Genotypisierungsmethoden nicht möglich. Wir haben VNTR-Typisierungmethoden 
entwickelt und eingesetzt, um die genetische Diversität der ghanaischen Isolaten zu 
untersuchen und haben bei einem neu identifizierten polymorphen Genlocus (ST1) und 
bei einem bereits beschriebenen Locus (MIRU1) unterschiedliche Allele gefunden. Bei 
den Stämmen aus Ghana wurden drei verschiedene Genotypen gefunden. Damit wurde 
zum ersten Male genetische Diversität bei M. ulcerans Isolaten innerhalb eines 
afrikanischen Landes nachgewiesen.   
Die Frequenz von IFN-γ sekretierenden T Zellen wurde durch ex vivo ELISpot Analysen  
mit PBMC von BU Patienten durchgeführt. Die PBMC wurden mit PPD, IPP und 
Virosmen stimuliert. Die Resultate zeigten erstmals, dass die systemische Reduktion der 
IFN-γ Antwort,  die mit der M. ulcerans Infektion assoziiert ist, nicht nur mit lebenden 
oder abgetöteten Mycobakterien und ihren Zellprodukten in Verbindung steht, sondern 
auch andere Antigene betrifft. Weiterhin zeigten wir, dass die Immunsuppression nach 
chirurgischer Behandlung wieder aufgehoben wurde und dass sie nicht mit einer 
Reduktion der IL-12 Sekretion assoziiert ist. Dies deutet darauf hin, dass die systemische 
Immmunsuppression keine Konsequenz eines genetischen Defekts der T-Zell Funktion 
ist, sondern in Zusammenhang mit der Anwesenheit von M. ulcerans Bakterien steht.  
In einer Longitudinal-Studie verglichen wir die Wiederherstellung der Effektorfunktion 
von Vγ2Vδ2 T Zellen in chirugisch behandelten BU Patienten und TB Patienten unter 
Chemotherapie. Zum Zeitpunkt der Diagnose war bei beiden Krankheiten die 
systemische Produktion von IFN-γ nach IPP Stimulation unterdrückt. Im Verlauf der 
Therapie normalisierte sich diese Reaktivität wieder, jedoch sehr langsam, so dass in 
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 xi
beiden Patienten-Populationen auch nach zwei Monaten die Normalwerte noch nicht 
völlig erreicht waren. Unsere Resultate weisen darauf hin, dass die bei BU zu 
beobachtende Immunsuppression nicht allein von dem von M. ulcerans produzierten 
immunsuppressiven Toxin, Mycolacton, verursacht ist. 
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1.1 Historical facts and epidemiology 
Buruli ulcer (BU) affects mainly the skin and it is caused by the environmental pathogen 
Mycobacterium ulcerans. It is the third most common mycobacterial disease, after 
tuberculosis and leprosy that occur in immuno-competent individuals (1). Historically, 
the disease was first discovered in 1897 by Sir Robert Cook, a British physician working 
in Uganda and later by Kleinschmidt in northeast Congo during the 1920s (1,2), but the 
first definitive description of cases and the etiologic agent was published  in 1948 by 
Professor Peter MacCallum and his colleagues in Australia (3). Between the 1960s 
through the 1970s new endemic foci were identified in several tropical countries 
including Uganda, the Democratic Republic of the Congo, and Papua New Guinea. Some 
of the reports were by Oye and Ballion, P. G. Janssens and Meyers et al who made the 
claim that, traumatic lesions might be involved in the transmission of M. ulcerans. By 
1974, more than four hundred cases had been described in Zaire (2,4). In the 1960s, many 
patients in refugee camps in an area near the Nile River in Uganda, called Buruli, had 
ulcers which were caused by M. ulcerans (4). The disease has since become to be known 
as BU. 
 
The global burden of BU is not clear, because of lack of efficient reporting system in 
most endemic countries (5). Nevertheless, it is now known that BU is endemic in at least 
thirty-two tropical countries of Africa, Western Pacific, Asia, the Indian Ocean and Latin 
America (figure 1) (5). The worst affected region is within countries lying along the Gulf 
of Guinea in West Africa, where BU has replaced leprosy as the second most common 
mycobacterial disease, after tuberculosis. Cases have been detected in all the countries 
with Ghana, Ivory-Coast, Togo, Cameroon and Benin recording the highest number of 
cases (6-11).  The prevalence of BU in some of the villages in this area is higher than that 
of tuberculosis and can affect more than 20% of the inhabitants. In Ivory-Coast, more 
than 15,000  (12) cases were reported between 1978 and 1999 while nearly 2,000 cases 
were reported within a 4-year period in one hospital in Benin (13). Very few cases have 
been reported in non-endemic areas in Europe and North America. Although, BU affects 
all age groups in both sexes, it has been reported to affect mainly children 15 years of age 
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and below in Africa (12). Most of the lesions are located on the legs, feet, arms and 
hands. 
 
 
Figure 1: Countries reporting Buruli ulcer. (Source: Johnson et al., PLoS Med, 2005) 
 
At an international meeting in July 1998 in Côte d'Ivoire, the Yamoussoukro Declaration 
on Buruli Ulcer was made, expressing the concern that little is known about this disease, 
and called on the international community to support control and research efforts (14). 
1.2 Buruli ulcer in Ghana 
The first documented case of Buruli ulcer in Ghana was a patient from Amasaman at the 
Korle-Bu Teaching Hospital in 1971 (15). The presence of additional cases along the 
Densu River in the area was considered a possibility. In 1989, van der Werf et al. 
published a series of 96 cases in the Afram valley at Agogo, in the Ashanti Akim North 
District in the Ashanti Region (16). Amofa et al also in 1993 described a major endemic 
focus in the Amansie West district in the same region (17). Since then, there have been a 
number of reports of scattered endemic foci in various parts of the country, particularly in 
the Ashanti Region. 
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Currently the disease represents a significant proportion of all disease cases registered in 
some endemic district health facilities. BU is spreading very quickly in Ghana. It was 
previously believed that the disease exists only in areas around swampy vegetation and 
tropical rain forest in the country. A national survey that was conducted in 1999 however 
established that the disease could be found in all ten administrative regions of the 
country. During the national survey, over 6000 BU cases were identified across the 
country (18). The overall prevalence of BU in Ghana was estimated to be 20.7 per 
100,000 populations making it the second most prevalent mycobacterial disease after 
tuberculosis. 
 
Efforts been made to control the disease in Ghana include offering of free treatment to 
BU patients and training of health workers to improve diagnosis. However diagnosis is 
usually delayed as a result of socio-cultural beliefs and distance to treatment centres (19). 
Diagnosis of BU is usually made on the basis of clinical case definition without 
laboratory confirmation.  
 
1.3 Pathogenesis and clinical Presentation 
1.3.1 Causative organism  
 
 
 
 
Taxonomically, M. ulcerans is a member of the phylum actinobacteria, in the order 
actinomycetales, suborder corynebacteriaceae and the genus mycobacterium. Like other 
Figure 2: Ziehl Neelsen stained smear of M. ulcerans from Buruli ulcer lesion observed 
under oil immersion (x1000). Note the acid fast bacilli in clumps.  
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mycobacterium species M. ulcerans has a high G+C content (65%) DNA and an unusual 
cell wall with a lipid-rich layer beyond the peptodiglycan layer. It has a long generation 
time, which has been estimated to be around 20 hours; it is therefore described as slow-
growing mycobacterium and the optimum growth temperature is between 31 and 33°C at 
pH of 5.4-7.4 (20). The organism usually grows under aerobic conditions but it grow 
better under micro-aerophillic conditions in liquid cultures (21). M. ulcerans belongs to a 
group of mycobacteria commonly referred to as opportunistic or occasional pathogens 
(22) and it is the only that does not have an extracellular infection and the pathology is 
mediated by toxin secretion (23). 
 
1.3.2 Clinical Presentation 
M. ulcerans may enter the skin by traumatic inoculation and that some biting insects may 
be involved (24). After successful entry, the organism confines itself to the subcutaneous 
tissues and the overlaying skin, where it multiplies. The incubation period is 
extraordinarily variable, and has been estimated to range from 2 weeks to 3 years, with an 
average of 2 to 3 months. The disease begins typically as a painless nodule under the skin 
at the site of the trauma. In some geographical areas the first manifestation is a papule 
rather than the firm, painless nodule. After a few weeks, the nodule gradually enlarges 
and erodes through the skin surface, leaving a well-demarcated ulcer with a necrotic 
slough in the base and widely undermined edges (20,25). This form of disease 
presentation is termed as localised.  Analysis of a large number of cases by Meyers and 
colleagues suggested that in some cases, infections spread rapidly and bypass the 
localized nodular-ulcerative stage. This disseminated form results in oedematous plaques 
that, if untreated, lead to ragged ulcers (figure 3) (26). Like the other steps in 
pathogenesis, the mode of spread is not apparent. M. ulcerans may spread to distant foci 
through the lymphatic and haematogenous pathway. Severe osteomyelitis is well-known 
and this may lead to amputation and other disabilities (27).  
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Oedema (c) Ulcer (d) 
Plaque 
Nodule (a) Papule (b) 
Plaque (e) 
Figure 3: Clinical forms of Buruli ulcer (Source: Portaels F, Johnson P, Meyer WM 
editors, 2001. WHO 
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1.3.3 M. ulcerans Toxin and Histopathology 
The pathological manifestation of M. ulcerans infection is thought to be mediated by 
toxin(s) production. A polyketide derived macrolide toxin, named mycolactone, with a 
potent tissue necrotizing activity, is deemed to be the major effector molecule. The genes 
that encode for the synthetic machinery of mycolactone are located on a circular giant 
plasmid with a molecular size of 174kb named pMUM001. More than half of the plasmid 
consist of genes that encode the enzymes required for the synthesis of mycolactone (28).  
This toxin produced a necrotising effect in guinea pigs, which was histologically similar 
to that seen in human patients (23). In addition it has in vitro activity against a number of 
immune cells, including those important for the control of mycobacterial infection(29) 
(30). Hence it has been postulated that secretion of the toxin by the invading microbe 
causes extensive necrotic damage to the host tissues particularly the dermis, panniculus, 
and fascia and the suppression of immune response. Histological analysis of early lesions 
reveals extensive cutaneous tissue necrosis with large numbers of extracellular bacilli in 
clumps and scanty inflammatory cells, which may be the result of the 
immunosuppressive action of the toxin. Analysis of tissue shows central necrosis of 
subcutaneous fat surrounded by granulation tissue with giant cells which lacks the typical 
caseation or tubercles seen in tuberculosis (31).   
 
1.4 Diagnosis 
In endemic areas, most cases are diagnosed on clinical evidence (32) and an experienced 
clinician can often make accurate clinical diagnoses of BU. Nevertheless, a number of 
diseases can be confused with Buruli ulcer disease in each of its clinical stages; thus, 
laboratory tests can help to confirm the diagnosis. The World Health Organisation 
(WHO) recommendations require positive results with at least two diagnostic test 
systems to reconfirm clinically diagnosed BU disease (20) These diagnostic systems are: 
1) detection of acid-fast bacilli (AFB) in a smear stained by the Ziehl-Neelsen technique 
2) positive culture of M. ulcerans 3) positive polymerase chain reaction (PCR) for the 
detection of M. ulcerans DNA and 4) histopathological analysis of excisional biopsy 
specimen. These methods vary in sensitivity, specificity, speed and cost. Specimen for 
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the first three diagnostic methods can be either surgically excised material or smears from 
ulcerative lesion.  
 
1.4.1 Direct Smear Examination 
The direct observation under the microscope for AFB after staining with carbol fucshin 
has been demonstrated to have a low sensitivity. It requires a concentration of 104 bacilli 
per millilitre suspension to give a positive smear test. In addition this method lacks 
specificity and as a number of other mycobacterial species can cause skin lesions, the 
detection of AFB alone does not establish M. ulcerans as the cause of the illness (33). 
However it is good for its rapidity and does not require sophisticated equipment, making 
it suitable for endemic regions in Africa where resources are scarce. 
 
1.4.2 Culturing of M. ulcerans 
Isolation of the causative agent is the final proof laboratory diagnostic method, which in 
addition offers the advantage of obtaining isolates that can be used for in-depth studies 
aiming to understand open questions, like the mode of transmission and drug 
susceptibility. Culturing of M. ulcerans is however difficult and slow and a number of 
studies have indicated that the sensitivity of culture is very low, coming up to only 35% 
(24). A major contributing factor is that samples sent to microbiology laboratories for the 
isolation of M. ulcerans are usually contaminated with faster growing microorganisms; 
hence there is need for selective decontamination to remove these contaminants prior to 
inoculation of the growth medium. At the same time M. ulcerans itself is to some extent 
susceptible to these harsh treatments, and even after decontamination, M. ulcerans 
cultures are frequently contaminated by faster growing bacteria and fungi (34). It takes 6 
weeks to 5 months for M. ulcerans cultures to be positive on solid medium.  
 
1.4.3 Detection of M. ulcerans DNA by PCR 
PCR assay is good for its rapidity and results can be obtained the same day. It is also 
sensitive and in theory requires only a very few cells to give a positive result. However it 
is expensive and therefore may not be used routinely in endemic countries in Africa. PCR 
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requires expensive equipments and elaborate infrastructures to prevent false results. On 
the other hand it will be useful for central or research institutes in endemic countries in 
Africa to establish PCR assays. This can be used for rapid differential diagnosis of cases 
that prove to be difficult to diagnose on clinical grounds alone. Several PCR-based assays 
detecting different genomic targets have been developed. M. ulcerans specific DNA 
targets include the 16s rRNA gene (35), the 65-kDa heat shock protein gene (36) and the 
insertion DNA sequence IS2404 (37). Presently, the recommended target for the 
diagnosis of BU is the insertion sequence IS2404, which is present in about 250 copies in 
the M. ulcerans genome (20), therefore improving the sensitivity of the assay. 
 
1.4.4 Histopathological Analysis 
"Characteristic" histopathologic changes are considered one of the confirmatory 
laboratory methods for Buruli ulcer disease; however, the features are non-specific and 
change as the lesion evolves from a nodule to an ulcer (20,38) . Several authors have 
described the histopathologic changes of Buruli ulcer disease as different patients 
progress through the different clinical stages (39). Necrosis of subcutaneous tissues and 
dermal collagen accompanied by minimal inflammation and AFB are considered the 
most reliable histopathologic features for the diagnosis of Buruli ulcer disease. 
Furthermore, the selection of specimen is very critical and quality of specimen varies for 
the different stages. Whilst biopsy specimen that include necrotic subcutaneous tissue and 
the undermined edge of ulcerated lesions is good for the diagnosis of ulcers, specimens 
from skin and subcutaneous tissue are suitable for the diagnosis of non-ulcerated lesions 
(20).  
 
1.5 Treatment 
1.5.1 Surgery 
Presently, the standard method of treating patients with BU is the surgical excision of 
infected tissue followed by skin grafting. This procedure apart from being invasive and 
very expensive, costing around $780 per treatment as reported in Ghana (40), has varying 
degree of success which depends on a number of factors including the experience of the 
CHAPTER 1. Introduction 
________________________________________________________________________ 
 10 
clinician. This is because there are no strict guidelines as to the extent of excision of 
lesions, thus the surgeon has to make a very good judgement between healthy and 
infected tissue. Recurrence rates ranging from 5-47% have been report in different 
studies. More importantly not all patients in rural endemic areas have access to health 
institutions that offer surgical services (41). As a result patients first try to solve their 
health problem within their communities by self- treatment or visiting local health 
providers, who treat them with herbal preparations (19). Such individuals may later 
present with very extensive lesions that requires a long post-operative care and restorative 
physiotherapy, which increases the cost of treatment. Some of them even end up with 
amputation and varying degrees of disability. A study conducted by Martson et al (8) 
reported that almost 30% of persons with healed lesions had chronic functional 
disabilities, including loss of eye and limbs. 
  
1.5.2 Drug Treatment 
Treatment with antimycobacterial agents has been considered disappointing especially at 
the advanced stage of the disease. Reports of human trials have been very discouraging; 
while clofazimine (42) and cotrimoxazole (43) was found to be ineffective, a 
combination of dapsone and rifampin was found to have limited efficacy for ulcers (44). 
On the contrary, M. ulcerans is susceptible to rifampicin, some aminoglycosides, 
macrolides and quinolones in vitro (45,46). The failure of these drugs to effectively 
inhibit M. ulcerans growth in humans has been hypothesised to be due to the inability of 
the drugs to penetrate the necrotic lesions and or the ongoing necrotic activity of the 
persistent toxin (47).  Findings from mice model studies suggest that a combination of 
rifampicin with either streptomycin or amikacin have strong bactericidal activity (48,49). 
Treatment of mouse footpad with a combination of rifampicin and amikacin for 12 weeks 
decreased progressively, the number of viable counts reduced and treated mice did not 
relapse after 17 weeks.   A clinical trial conducted by Etuaful and colleagues reported that 
a minimum of 4 weeks treatment with rifampin and streptomycin combined, inhibits the 
growth of M. ulcerans in pre-ulcerative lesions, as confirmed by at least one of the 
following; direct AFB staining, PCR and culture (41). However, they could not confirm 
that this combination could replace surgery and suggested it to be used as an adjunct to 
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surgery.  Based on this successful report and other observations, a recent WHO 
guidelines have been developed that required an eight weeks course of treatment with 
rifampicin and streptomycin (47). First clinical experience indicates that this treatment 
leads to healing without subsequent surgery in about 50% of cases.  
 
1.6 Transmission 
Currently the exact mode of transmission of M. ulcerans is still not clarified. However 
BU affects people in scattered foci and endemic foci are usually associated with wetlands 
with hot and humid climates (50). In Uganda, hundreds of cases occurred among refugee 
populations camping close to the Nile River and the incidence of cases subsided when the 
refugees were moved out of the area (4).  Upsurge of cases have also being reported in 
areas that the environment has been disturbed; examples include, flooding, damming of 
rivers, introduction of rice swamp fields and irrigation systems (1).  In Nigeria, increased 
incidence occurred when a small stream was dammed to make an artificial lake (51). So 
also in Philip Island, the formation of a small swamp led to increased cases, which 
declined when the irrigation was improved (52).  
 
M. ulcerans is an environmental mycobacterium and the involvement of aquatic species 
in endemic areas as either environmental reservoirs and/or vectors for transmission seems 
likely. M. ulcerans has been detected in aquatic bugs (53), mollusc (54), fish (55)and 
biofilm on vegetation (56). These have been determined mainly using PCR based on the 
detection of IS2404 DNA sequence (57), which is now known not to be very specific for 
M. ulcerans (58). Only two pure cultures of M. ulcerans have been obtained from 
environmental sources so far (47).  In a laboratory experimental model, an aquatic insect 
was able to infect the tail of laboratory mice by biting (59). Thus infected insects may 
accumulate M. ulcerans in their salivary glands and pass on to man through biting. This 
hypothesis is strengthened by the detection of M. ulcerans in the salivary gland of an 
aquatic insect, Naucoris spp (60).  The extent of man to man transmission is not proven 
but evidence of developing BU after a human bite is known; if man to man transmission 
is a natural occurrence needs to be established (61).  
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There is no available instituted measure for prevention of BU due to the inadequate 
knowledge on transmission and the lack of an effective vaccine against BU. A study 
conducted in Ivory-Coast however revealed that covering of the exposed body sites by 
wearing of long trousers in endemic communities is protective (8). Also the M. bovis 
BCG vaccines seems to offer some degree of protection, especially against systemic 
infections (62). 
 
 1.7 Genetic Diversity in M. ulcerans Isolates 
M. ulcerans seems to be one of the most extreme examples of bacterial homogeneity. 
This low degree of genetic polymorphism in the organism’s DNA sequence has restricted 
the expected discriminating power of a number of markers and methods that are routinely 
used for genetic fingerprinting of other bacterial species. Global analyses of isolates have 
resulted in the sub-grouping of M. ulcerans according to their geographical origin, at 
continental level. African isolates are usually grouped together as one genotype.   Some 
of the markers and procedures employed include:  
 
Restriction Fragment Length Polymorphism (RFLP): This technique uses variability in 
the nucleotide sequence and frequency of certain DNA sequences in bacterial 
chromosomes. These differences are revealed by using rare cutting restriction enzymes 
(RE) that cut DNA at specific recognition sites (63). The resulting genomic DNA 
fragments are subsequently analysed by gel electrophoresis. Differences in fragment sizes 
and numbers occur due to base substitutions, additions, deletions or sequence 
rearrangements within RE recognition sequences.  Usually the analysed DNA sequence is 
used as a probe in a southern hybridization procedure to reduce the number of fragments 
and also determine the polymorphism of the marker in the genome. RFLP is most suited 
for studies at the intra-specifies level or among closely related taxa. The pioneering work 
of Jackson et al used an RFLP-based method with the plasmid pTBN12 as a probe for 
typing isolates from Africa and Australia (64). This study identified 11 RFLPs 
distinguishing the African strains from the Australian isolates. Furthermore this study 
was able to differentiate the isolates from Victoria into three subgroups and was able to 
distinguish isolates from Zaire and Benin. A PCR based genotyping assay, using the 
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IS2404 and IS2606 insertion sequences, developed by Stinear et al recognised nine 
distinct profiles that also differentiated M. ulcerans strains according to the geographical 
origin (65) . Chemlal et al used only the insertion sequence IS2404 as a probe in an RFLP 
based fingerprinting assay and divided the isolates into 6 types: African, Australian, 
Mexican, South American, Asian and South-east Asian types (66).   
 
Sequencing of the 16SrRNA gene: This method employed the slow evolution of this gene 
over time to identify the relatedness of different organisms. This method showed that M. 
ulcerans is very closely related to M. marinum and just differ in a single base pair at 
position 1248. Portaels et al sequenced the 3’end of the 16SrRNA gene of 17 different 
isolates and were able to differentiate them into three types: the African, Australian and 
American type (67).  
 
PCR restriction profile analysis: This method employed a triple restriction of the 
amplified product of the 3’ end region of the 16SrRNA gene and gave three different 
profiles according to the geographic origin. It could not differentiate M. marinum from 
M. ulcerans isolates originating from Southeast Asia and South America (68).  
Amplified Fragment Length Polymorphism: In this technique whole genomic DNA is 
restricted by two enzymes, addition of double stranded oligo-nucleotide adaptors to the 
ends of the fragments followed by selective amplification of the modified fragments with 
primers specific to the adaptors. Huys et al evaluated this procedure for inter and intra-
specific differentiation of M. bovis, M. tuberculosis and M. ulcerans and reported that 
AFLP it is good for inter-species differentiation but not intra-species differentiation; 
clearly differentiate M. ulcerans from the M. tuberculosis complex and classified the 12 
M. ulcerans isolates into two continental types (69).  
 
Multi-locus sequencing typing (MLST): This method employs the variability in the base 
sequence in a set of housekeeping genes. MLST was used to type M. ulcerans isolates by 
sequencing eight genes and this resulted in the identification of six genotypes according 
to their geographical origin; that is Africa, Australia, Mexico, South America, Asia and 
South-east Asia (70). 
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Analysis of the polymorphism in the IS2404 and the frequently GC rich region in 
mycobacterium species by amplification of the genomic regions between these genomic 
markers yielded ten different band patterns. All the African isolates produced the same 
band pattern, and isolates from Papua New-Guinea produced two different band patterns 
(71). 
 
MIRU-VNTR:  This is a PCR-based method that determines genomic polymorphism 
based on differences in the copy number of repetitive units of 46-100 bp. It is faster than 
most of the methods described above and more importantly has been found to be 
reproducible between different laboratories. In addition, it has been shown to have a high 
discriminating power in the members of M. tuberculosis complex.  Two independent 
studies that employed this method also could not differentiate African strains from both 
west and central Africa. In the first study 39 different isolates analysed with four 
polymohphic MIRUs identified 7 genotypes worldwide (72). In the second study nine 
VNTRs sequences obtained from the genome sequence of the related species M. marinum 
also gave similar findings (73).   
These findings are indicative for a clonal population structure of M. ulcerans. Thus there 
is no method that can be used currently for micro-epidemiological investigations like 
tracing the transmission pathways of this pathogen. 
 
1.8 Immune responses to M. ulcerans 
Immune response to M. ulcerans infection is characterised by low inflammatory response 
and lack of granuloma formation in early lesions. Gooding et al found that infection with 
M. ulcerans is associated with T cell anergy as PBMCs from individuals with BU 
exhibited reduced lymphoproliferation and production of IFNγ follwing stimulation with 
live M. ulcerans or M. bovis (74). A follow-up study by the same group analysed the Th1 
and Th2 response of subjects with active and healed Buruli ulcer and household contacts. 
Following stimulation with M. ulcerans or Mycobacterium bovis BCG it was shown that 
Th1 anergy persist even upon healing (75). In Guyana, Prevot et al demonstrated that in 
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active BU, in vitro production of IL-10 in PBMCs after stimulation with M. ulcerans was 
significantly increased compared to tuberculin positive controls and the reverse was true 
for IFNγ (76). This systemic finding paralleled in vivo mRNA levels of these cytokines. 
In resected tissues, the level of IFN-γ mRNA was higher, and IL-10 mRNA was lower in 
nodular lesions than ulcerative lesions after stimulation with heat-killed M. ulcerans.  
Westernbrink et al in a whole blood assay demonstrated a systemic reduction in IFNγ 
production in response to PPD antigens in patients with early lesions compared to those 
with later stage lesions (77). These findings from different studies suggest that Th1 
response is down regulated early in BU disease partly by IL-10 secretion or by immune 
modulation activities of M. ulcerans. 
 
Mycolactone toxin described in association with the pathology of BU has profound 
effects on immune cells in vitro(23). An investigation by Pahlevan et al on the activity of 
partially purified M. ulcerans toxin on different human immune-competent cells found 
that the toxin produced greater than 95% inhibition of LPS-induced release of TNF-α and 
IL-10 from human monocytes. It also causes loss of adherence of monocytes without cell 
death (30).  Addition of mycolactone to macrophages and fibroblast affected the 
organisation of the cytoskeleton that leads to growth arrest and apoptosis (78). 
Furthermore, IL-2 production from activated T lymphocyte was blocked by the toxin 
(30,78,79) This was after Pimsler et al had already demonstrated that M. ulcerans culture 
filtrate causes suppression of T cell response to Concanavalin A and inhibited 
phagocytosis of latex beads by macrophages (80). In mouse model studies, it appears 
upon infection, some M. ulcerans is initially internalised and transported to lymph nodes 
for initiation of adaptive immune response by professional APCs, however, expression of 
mycolactone inhibits further phagocytosis, enhance phagocyte necrosis and apoptosis and 
inhibits expression of pro-inflammatory cytokines such as TNF-α (29,81). 
 
In spite of this local immune suppression, there is evidence that sensitivity to M. ulcerans 
antigen develops during infection (82). BU patients have been shown to response to a 
crude antigen preparation, Burulin, from M. ulcerans. This positive skin response was 
found mainly in patients at the late stages of disease or when healed (83). This suggests 
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that a delayed type hypersensitivity response may be important in healing. In addition, 
spontaneous healing has been observed confirming the pivotal role of the immune system 
in the control of BU (22). The histological appearance of later lesions is also found to be 
similar to that of other mycobacterial diseases with small numbers of extracellular 
organisms and the formation of granulomas (84,85). The importance of Th1 in protective 
immune response against MU is confirmed recently by a report of extensive multifocal 
lesions associated with HIV infection (86). 
 
BU patients do mount humoral immune responses to M. ulcerans. Work carried out by 
Dobos et al in Ivory–Coast, demonstrated that BU patients produce antibodies against M. 
ulcerans independent of the disease stage (87). This was evident by 43 out of 61 BU 
patients testing positive to M. ulcerans culture filtrate. This was confirmed in Australian 
patients where 9 out of 11 patients had antibodies to M. ulcerans (74).  
 
1.9 Immune Response to intracellular mycobacteria 
Infection with M. tuberculosis (Mtb) is mainly by inhaling bacilli containing droplet 
nuclei. Inside the host they are engulfed by alveolar macrophages/dendritic cells (88). 
These cells may kill, process and present mycobacterial antigen at the regional lymph 
node to initiate adaptive immune response. Only 5-10% of individuals who are infected 
with the bacilli progress to disease and the remaining 90% even though may not progress 
to disease are unable to completely eradicate the pathogen (89). This persistent infection 
has been termed latent Mtb infection and reflects successful immune-mediated 
containment of Mtb. Control of infection with mycobacteria relies heavily on the cellular 
immune system; that is the interaction of lymphocytes and M. tuberculosis-infected 
macrophages and dendritic cells to form granulomas (90).  In addition to walling of the 
infected site, granulomas provide a microenvironment to facilitate interactions between 
the infected macrophages and other participating immune cells (90). In fact, granuloma 
formation is considered as hallmark of protective immuno-pathological response of the 
host following infection with Mtb. A range of experiments in animal models and humans 
support crucial roles of CD4+, CD8+ and γδ T cells in immune protection (90-92). 
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1.9.1 Role of the different T cell subsets in immune protection against intracellular 
mycobacteria 
CD4+ T cells play a central role in immune control of M. tuberculosis infection.  Mtb-
derived peptide antigens degraded in the phagolysosomal compartment of infected 
macrophages are presented together with MHC II to CD4+ T cells, resulting in their 
activation (93). The importance of this T cell subset is convincingly demonstrated by the 
loss of CD4 T cells in HIV infection and the corresponding susceptibility to TB. These 
observations have been confirmed in mice model studies using adoptive transfer and 
knock out models in CD4-/- and MHC II-/- (94).  The main function of the activated 
CD4+ T cells is the release of cytokines, like INF-γ and TNF-α, which limit intracellular 
Mtb growth by the up-regulation of microbicidal mechanisms in macrophages (95). The 
critical role of these cytokines in mycobacterial infections have been revealed by studies 
in humans subjects with either mutations in the INF-γ receptor (96,97) or receiving anti-
TNF-α therapy with increased vulnerability to mycobacterial infections (98). CD4+ T 
cells may also contribute to the control of mycobacterial infections in non IFNγ 
dependent mechanisms (99), possibly by interactions such as CD40-CD40L and OX40-
OX40L (91). Finally, antigen specific CD4+ T cells may be involved in lysis of infected 
macrophages through the Fas/Fas-ligand interactions  and exocytosis of cytolytic  
granules (91).  
 
CD8+ T cells are present in mycobacterial granulomas, where they have access to and are 
poised to prevent dissemination of infected cells (100). There are two subsets of CD8+ T 
cells that participate in immune response against mycobacterial infection. One subset is 
restricted by MHC class I molecules and recognise bound peptide antigens. The other 
subset is restricted by CD1 molecules, which have been shown to present 
mycobacterially-derived lipids, glycolipids and lipopeptides (100,101). Functionally, 
these T cell subsets have been found to lyse infected macrophages and dendritic cells, 
reducing levels of intracellular  bacterial load (102). Lysis of infected cells by both 
subsets is mediated by the peforin/ granzyme pathway and Fas/FasL interactions (103).  
 
γδ T cells play an important role in host response to TB, especially at the early phase. 
Vγ9Vδ2+ T cells are activated by Mycobacterium tuberculosis and recognise 
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mycobacterial nonpeptide phosphoantigens (92). Mycobacterial responsive Vγ9Vδ2 T 
cells are usually found in disease lesions. Vδ1 T cells are the predominant γδ T cells in 
the cerebro-spinal fluid of normal individuals, however, Vγ9Vδ2 T cells become the 
major subset in the CSF of tuberculosis meningitis patients (104). Vγ9Vδ2 T cells from 
children with tuberculosis have reduced IFN-γ production and granulysin expression, 
which reversed after successful chemotherapy (105). Functionally, mature Vγ9Vδ2 T 
cells display a potent natural killer (NK)-like cytotoxic activity (106) and produce 
secreted cytokines that may be important for cellular traffic and granuloma formation 
(104).  Nothing has been reported to date on the role of these cells in immunity to M. 
ulcerans. 
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2.1 Goal 
The purpose of this study was to contribute toward the understanding of the bacteriology 
of M. ulcerans and host immune response to M. ulcerans infection for effective 
management and control of Buruli ulcer (BU). 
 
2.2 objectives 
1. To optimise primary isolation of M. ulcerans from clinical samples by evaluating 
different culturing methods. 
2. To confirm clinical diagnosis by culture, microscopy and the polymerase chain 
reaction. 
3. To analyse the susceptibility pattern of M. ulcerans isolates to antimycobacterial 
drugs. 
4. To develop and characterise M. ulcerans isolates by Variable Number of Tandem 
Repeats (VNTR) sequence typing. 
5. To study cell mediated immune responses in BU by upon antigen stimulation of 
PBMCs from patients using ex vivo ELISpot analysis, T cell proliferation assays 
and cytokine measurements by ELISA. 
6. To determine the kinetics of recovery of γδ T cell effector function in BU patients 
after surgery. 
7. To analyse the serum cytokine levels of BU patients and compare to that of 
household contacts and non-exposed controls.  
 
 
CHAPTER 3. Evaluation of methods for primary isolation 
________________________________________________________________________ 
 31 
 
Chapter 3: Evaluation of decontamination methods and growth media for 
the primary isolation of Mycobacterium ulcerans from surgical specimens 
 
 
Dorothy Yeboah-Manu1, Thomas Bodmer2, Ernestina Mensah-Quainoo3, Samuel 
Owusu1, David Ofori-Adjei1 and Gerd Pluschke4 
 
Noguchi Memorial Institute for Medical Research, Legon, Ghana1, Institute for Infectious 
Diseases, University of Bern, Bern, Switzerland2, Ga District Health Services, Amasaman, 
Ghana3 and Swiss Tropical Institute, Basel, Switzerland4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This article has been published in the Journal of Clinical Microbiology 2004 Dec; 42(12):5875-6 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3. Evaluation of methods for primary isolation 
________________________________________________________________________ 
 32 
Abstract  
We evaluated four decontamination methods and one non-decontamination procedure in 
combination with four egg-based media for the primary isolation of M. ulcerans from tissue 
specimens. With mycobacterial recovery and contamination rates of 75.6% and 2.4%, 
respectively, the combination of oxalic acid decontamination with LJ-glycerol medium 
yielded the best results.  
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Currently laboratory diagnosis of Buruli ulcer (6) caused by Mycobacterium ulcerans relies 
on the detection of acid-fast bacilli in stained smears, the isolation of the pathogen from 
infected tissue or tissue exudates by culture, the identification of characteristic 
histopathological changes and/or the detection of mycobacterial DNA by the IS2404 PCR. A 
number of studies have indicated that the sensitivity of culturing of the slow growing M. 
ulcerans is <40 % when compared with the IS2404 PCR (1, 7 & 8). The purpose of this study 
was to optimize the cultivation procedure of M. ulcerans for surgical specimens.  
 
Tissue specimens, collected from suspected active Buruli ulcer cases diagnosed by the WHO 
clinical definition (6) at the Amasaman Health Centre in the Ga district of Ghana between 
September 2002 and April 2003 were analyzed. Cultures were set up with a total of 41 
surgical specimens collected from 36 patients. Patients usually sought medical treatment late 
as more than half of them presented with ulcerative lesions. Care was taken not to 
contaminate the excised specimens, which were stored at 4°C in 7 ml modified Dubos 
transport medium supplemented with 10% oleic acid-albumin-dextrose-catalase (Lenexa, 
KS), 2% PANTA Plus (Becton Dickinson, Franklin Lakes, NY) and 0.5 % agar-agar (Difco). 
All samples were processed within one week after surgical excision. Specimens were cut into 
smaller pieces, homogenized and suspended in 8 ml of Dulbecco’s phosphate buffered saline 
(PBS). 100 µl of the resulting suspension was inoculated directly, i.e. without prior 
decontamination, onto selective Lowenstein-Jensen (LJ) medium supplemented with 0.75% 
glycerol and 2% PANTA Plus. The remaining suspension was divided equally into four 
aliquots (about 2 ml in volume). Aliquots were decontaminated with the Petroff (2), reversed 
Petroff (RP; 5), NALC (2) or Oxalic acid method (OA; 5). After decontamination, the 
homogenates were concentrated by centrifuging, and 100 µl aliquots of the 1 ml suspensions 
were inoculated in duplicate on the four solid media (9): LJ with 0.75% glycerol (LJG) or 
0.5% pyruvate (LJP) and Ogawa medium with 1.3% glycerol (OG) or 0.5% pyruvate (OP). 
Inoculated tubes were incubated at 33ºC and the number of tubes that yielded M. ulcerans, 
mycobacterial colony counts per tube and the time to the appearance of visible colonies were 
determined. All suspected M. ulcerans isolates were confirmed by sequencing the first 500 
base pair of the 16S rRNA gene using the MicroSeq 500 16S rDNA Bacterial Sequencing Kit 
(PE Applied Biosystem) as described earlier (4).  
 
LJG gave the best (p<0.001) overall mycobacteria recovery rate when results obtained with 
the different decontamination methods used were cumulated (Table 1). It supported the 
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growth of M. ulcerans from all 32 specimens from which a positive culture could be obtained 
by any of the conditions tested (n=41). When the results of the four different media used were 
cumulated (n=144 tubes per decontamination method), 4 (2.4%), 5 (3%), 24 (14.6%) and 25 
(15.2%) tubes were found to be contaminated with OA, RP, P and NALC, respectively (Table 
2). In combination with the best performing medium, LJG, the recovery rates were 75.6%, 
68.3%, 65.8% and 63.4% for OA, P, RP and NALC, respectively. Of the 41 PANTA-
supplemented LJG culture tubes inoculated with non-contaminated samples, 25 (61 %) grew 
M. ulcerans, 12 (29.2 %) got contaminated and 4 tubes (9.7%) had no growth. 
Macroscopically detectable M. ulcerans colonies appeared faster (p<0.05) with the non-
decontamination method (six weeks) than with the four decontamination procedures (median 
time with LJG: eight weeks) and the mean number of mycobacterial colony forming units 
obtained by this procedure was also found to be slightly higher than with the decontamination 
procedures. However, due to the high contamination rate, the number of positive cultures was 
slightly lower (odds ratio of 2.7; 95% confidence interval, 0.8-8.9) than that with the best 
performing decontamination method, OA in combination with LJG.  
 
32 of 41 (78%) samples analyzed were AFB positive by microscopy after Ziehl-Neelsen 
staining (1) and the same number was culture positive (31 of these 32 were positive by the 
best performing cultivation methodology, LJG in combination with OA). Altogether, pure 
cultures were obtained from 30 of the 41 samples. Three of the culture negative samples were 
microscopy positive (for one of these, all culture tubes gave rise to non mycobacterial 
overgrowth) and three of the microscopy negative samples were culture positive. Out of the 
six cultures and microscopy negative samples only one was positive by IS2404 PCR (8). We 
assume that the lesions from which the remaining five samples had been collected were not 
related to Buruli ulcer. Only slight differences in the performance of microscopy and culture 
in relation to the type of lesion was observed (Table 3). Culture positivity was slightly higher 
with ulcerative lesions than with nodules and plaque lesions (86 versus 70%); however this 
was not statistically significant.     
    
In the present study we followed strict sampling procedure: i. great care was taken to avoid 
exogenous contamination when recovering samples from the surgically excised tissue; ii. the 
collected tissue samples were immediately suspended in a medium containing antibiotics, 
kept refrigerated and transported on ice; iii. samples were processed within seven days after 
excision in a cultivation facility in Ghana. Adherence to these strict rules resulted in a 
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comparatively low contamination rate; only one nodule specimen was lost due to bacterial 
overgrowth of all culture tubes.  
 
We conclude that successful primary isolation of M. ulcerans depends on the emphasis put on 
optimum sampling procedures and specimen handling prior to cultivation. The direct 
inoculation of specimen onto a selective LJG medium containing PANTA in addition to the 
use of oxalic acid for decontamination in combination with LJG medium may further increase 
recovery rates, particularly for specimens with a low mycobacterial load, and reduce time to 
recovery of M. ulcerans.  
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Table 1:  
Effect of the growth medium on the recovery of M. ulcerans. 
 
Medium Number of culture 
positive samples 
(n=164) 
Mean CFU per 
culture tube 
Time (weeks) after which 
macroscopic growth was 
observed (mean in brackets) 
LJG* 112 (68.3%) 215 5-14 w (7.4 w) 
LJP* 78 (47.6%) 100 6-13 w (9.4 w) 
OG* 88 (53.6%) 145 8-19 w (12.5 w) 
OP* 52 (31.7%) 80 8-18 w (11.8 w) 
  
*Results with the four different decontamination methods are cumulated 
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Table 2:  
Effect of the decontamination method on the recovery of M. ulcerans. 
 
Decontamination 
method 
Number of culture 
positive samples (n=164) 
Number of cultures with 
contamination 
P* 81 (49.4%) 24 (14.6%) 
RP* 86 (53.8%) 5 (3.0%) 
NALC* 78 (47.6%) 25(15.2%) 
OA* 86 (53.8%) 4(2.4%) 
 
*Results with the four different media are cumulated 
 
 
Table 3.  
Performance of diagnostic microbiology in relation to the type of BU lesion.  
 
 
Disease stage  
Number of 
microscopy positive 
specimens 
Number of culture positive 
specimens (all methods) 
Nodules and plaques  16/20 (80%) 14/20 (70%) 
Ulcerative lesions  16/21 (76%) 18/21 (86%) 
Total  32/41 (78%) 32/41 (78%) 
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Abstract 
Clinical diagnosis of M. ulcerans infection is currently accepted as sufficient basis for treating 
the disease. Inadequate laboratory resources in the highly endemic areas of Africa often limit 
possibilities for in-country confirmation of clinical judgment. However, accurate pre-
treatment diagnosis is highly desirable to prevent unnecessary surgical and/or anti-
mycobacterial drug treatment of patients with non-Buruli ulcer conditions. Here we analyzed 
records of 99 Buruli ulcer patients diagnosed clinically and treated surgically at Amasaman 
Health Centre in Ghana, for whom post-treatment diagnostic laboratory tests were performed. 
Comparison of clinical diagnoses with test results obtained by an in-country laboratory on 
samples of excised tissue showed a high accuracy of clinical judgment. Among lesions with 
three laboratory tests (microscopy for acid fast bacilli, culture and IS2404 polymerase chain 
reaction) done, 94% had at least one test positive and 83% had at least two tests positive. We 
conclude that correct clinical diagnosis of Buruli ulcer by well trained health workers is 
achievable. Quality of clinical diagnosis should be monitored by intermittent testing in 
national reference laboratories. We also advocate further research to develop highly predictive 
but simple diagnostic tests to aid fast pre-treatment confirmation of M. ulcerans infection at 
peripheral treatment centers in the highly endemic areas of Africa. 
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Introduction  
Currently, the diagnosis of Buruli ulcer (BU), caused by Mycobacterium ulcerans, is mainly 
clinical, and this is considered sufficient basis for treatment decision (1,2). The brunt of the 
global burden of BU falls on West Africa, where cases occur in thousands in remote areas (3). 
These countries lack the resources to meet the cost of treatment, which is high (4). In 
particular, laboratories are inadequate or absent at peripheral centers where the majority of 
cases are treated. Pre-treatment diagnosis of non-ulcerated lesions is further limited. Punch 
biopsy is suggested to obtain specimens, but this carries risks such as dissemination of M. 
ulcerans, bleeding and precipitate ulceration. Clinical judgment will thus likely remain the 
mainstay of pre-treatment diagnosis – especially in endemic developing countries – until these 
constraints are resolved. Accuracy of this method of diagnosis is therefore of interest.  
 
Although clinical diagnosis is considered unchallenging (5), incidents of misdiagnosis have 
been reported. BU cases have been missed initially (6-8). Conversely, presumed BU lesions 
may prove to be other conditions (9-13). Even with careful assessment, nearly a third of the 
cases in a study on the efficacy of antibiotic treatment (14) turned out to be other conditions, 
indicating that in particular the clinical diagnosis of pre-ulcerative lesions can be error-prone. 
The World Health Organization (WHO) requires confirmation of suspected cases with 
positive results of at least two tests (15) from among microscopy with staining for acid fast 
bacilli (AFB), culture, histopathology and IS2404 polymerase chain reaction (PCR).  
 
Ga West Health District (GWD) in Ghana is highly endemic for BU.  A survey in 1997 which 
found 340 active cases showed the disease clustered in rural communities in the lowland basin 
of the Densu River. (Mensah-Quainoo E, unpublished). A national case search in 1999 
recorded 1113 cases in the district, (467 being active) constituting 20% of the total national 
figure of 5619 (16). In the endemic communities BU is recognized well, with several local 
names, such as Aboa gbonyo, Aboa fon, Odonti fla, Odonti hela, Detifu dor and Tsina asane, 
which aptly describe its features. As reported also for other BU endemic areas, many of the 
patients commonly seek medical care only after healing fails with traditional treatment. BU 
cases in GWD are treated at a rural health facility, Amasaman Health Centre (AHC), where 
surgical services were established to counter difficulties in referring cases for treatment 
elsewhere. Treatment decision at this centre relies exclusively on clinical diagnosis. In this 
study, cases diagnosed clinically over a three year period were validated with results of 
analysis of specimens of the excised tissue in an in-country research laboratory.  
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Materials and Methods  
Patients 
All patients in this study were reviewed by one clinician who made the final diagnostic 
decision. Cases/lesions were classified according to the standard WHO definitions (2). 
Patients clinically diagnosed as having BU and surgically treated at AHC during the 3-year 
period beginning of July 2001 to end of July 2004, who had single lesions on first 
presentation, and at least two diagnostic tests done, and whose complete clinical records were 
available, were included in the study. Only one patient (N3 in Table 5) received anti-
mycobacterial therapy prior to surgical excision. We reviewed patients’ clinical notes, Bu 01 
forms (1) and laboratory records. 
 
Laboratory diagnostic methods 
Tissue samples of about 2 cm3 were taken for laboratory analysis from the centre of pre-
ulcerative lesions, and from the active edge of ulcers during surgical treatment. Samples were 
cut to include dermis and obviously diseased subcutaneous fatty tissue, with care to avoid 
contamination. Samples were placed in modified Dubos transport medium as previously 
described (17), kept in the cold and transported within one week to the Noguchi Memorial 
Institute for Medical Research (NMIMR) in Legon, Ghana, where culture, Ziehl-Neelsen 
staining and IS2404 PCR were performed. For each patient, all tests done in each instance 
were performed on the same sample.  
 
Cultivation was done as described previously (17). Specifically, half of the diagnostic tissue 
specimen (about 1cm3) was cut into smaller pieces, homogenized and suspended in 
Dulbecco’s phosphate buffered saline (PBS). The suspension was decontaminated by the 
oxalic acid method. After decontamination, the homogenate was concentrated by 
centrifugation, and 100 µl aliquots of the 1 ml suspensions was used to inoculate in duplicate 
LJ tubes. These were incubated at 32ºC and all suspected M. ulcerans isolates were confirmed 
by IS2404 PCR. Two drops of the remaining suspension was used to prepare two slides per 
sample for Ziehl-Neelsen (ZN) staining. Stained smears were read as previously described 
(17).  
 
The remaining half of the tissue specimen was used for IS2404 PCR. DNA was extracted by 
heating the remaining sample for 1 h at 95°C in 500 µl of an extraction mixture (50 mM Tris-
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HCl, 25 mM EDTA, and 5% monosodium glutamate). After cooling 100µl of a 50 mg/ml 
lysozyme solution was added and incubated for two hours at 37°C.  70 µl of proteinase K-10x 
buffer (100 mM Tris-HCl, 50 mM EDTA, 5% sodium dodecyl sulphate [pH 7.8]) and 10 µl of 
a 20 mg/ml proteinase K solution was then added and incubated at 45°C overnight. The 
bacterial cell wall was fully disrupted by adding 200 µl of 0.1 mm-diameter zirconia beads 
(BioSpec Products) to each sample and vortexed at full speed for 4 min. Beads and undigested 
tissue fragments were removed by brief centrifugation, and the supernatants were transferred 
to fresh tubes for phenol-chloroform (Fluka) extraction. The DNA contained in the upper 
phase was precipitated with ethanol and re-suspended in 100 µl of water. The IS2404 
sequence was amplified in a 50µl reaction volume using the Qiagen Taq DNA polymerase kit. 
The primer sets used for the amplification were as described before (Ross et al, 1997). The 
reaction mixture contained a 1.0 µM concentration of each primer, 200 µM concentration of 
each deoxynucleoside triphosphate, 1.5 mM MgCl2,  1x PCR buffer, 1 U of Taq DNA 
polymerase (Qiagen, Hilden, Germany), and approximately 50 ng of DNA. Thermocycling 
parameters were 95°C for 3mins; 35 cycles of 1min at 94°C, 1min at 60°C, and 1min at 72°C; 
and 7min at 72°C. Ten microliters of amplified DNA was subjected to electrophoresis in a 2% 
agarose gel and detected by ethidium bromide staining and UV transillumination. The 
amplicons were sized by comparing to a 1-kb ladder.  
 
The results of the laboratory tests of treated patients were compared with the clinical 
diagnosis retrospectively, to assess the validity of the latter. The levels of agreement between 
different tests were quantified using Kappa statistics; where k = 0 is equivalent to the level of 
agreement expected by chance and k = 1 indicates perfect agreement.  The NMIMR ethical 
review board gave permission for performing the study. 
 
CHAPTER 4. Clinical and laboratory diagnosis of Buruli ulcer 
 44 
Results 
Patient population and clinical features 
Between July 2001 and July 2004 a total of 131 BU patients were clinically diagnosed and 
treated at AHC. Administrative difficulties prevented tests to be done for 20 of the 131 cases. 
Of the remaining 110 patients, one patient with incomplete notes and 10 who had multiple 
lesions were excluded. Ninety-two of the 99 remaining patients had one sample each tested; 
the rest 7 had additional samples from recurrent lesions tested. Forty-two males aged 3 to 70 
years and 57 females aged 2 to 75 were included in the study. Median age was 11 years and 
62.6 % were aged 14 years and below (Figure 1) Altogether, 91.7% of the 108 lesions 
included in the study were on the limbs (Table 1). The left leg and right arm were more often 
affected than the corresponding opposite limbs. There was a statistically significant difference 
between upper limbs and lower limbs in the distribution of lesions between the left and right 
sides (chi square = 6.3, p = 0.01) Forty-eight per cent (52/108) of lesions were pre-ulcerative, 
33.3% (36/108) in earlier ulcer stages and 18.5% (20/108) were chronic ulcers. Clinical 
records were compared with corresponding laboratory test results. 
 
Performance of laboratory tests  
As the history, clinical features and course of illness left no doubt that the primary and 
recurrent lesions in the 7 patients with recurrences were caused by M. ulcerans infection, 
results of these are presented separately (Table 2). The culture for one sample was 
contaminated and two samples had no PCR done. Thus, 17 AFB and 15 PCR tests were 
carried out, and 16 cultures were evaluable. Thirty-eight (79.2%) of these 48 evaluable tests 
were positive. Each test method yielded at least one false negative result.  
 
Next, we compared the clinical diagnoses at first presentation for all 99 patients with their 
laboratory test results. For the seven patients who had recurrences, only the test results of their 
primary lesions, which posed a true challenge for clinical decision, were included in this 
assessment. For the 99 lesions, AFB and culture were performed in all cases, whereas PCR 
was done for 85. The cultures for 2 of the 85 lesions were contaminated. This resulted in 83 
patients with all 3 tests done and evaluable; 14 patients with only AFB and culture done and 
evaluable; and 2 patients with AFB and PCR evaluable. Of the evaluable tests, 78.8% (78/99), 
79.4% (77/97) and 72.9% (62/85) were positive for AFB, culture or PCR, respectively (Table 
3). In 36.4% (36/99) of patients, negative results with one test were associated with positive 
results for one or both of the two other tests; an indication of false negative results. Among 
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the 83 patients for whom all three tests were carried out, 94.0% (78/ 83) had at least one test 
positive, 83.1% (69/83) had at least two tests positive, and 53.0% (44/83) had all three tests 
positive (Table 3). Among the 14 cases with only AFB and culture performed, 10 had both 
tests positive, two had culture alone positive and two had both tests negative. The two patients 
with contaminated cultures tested positive for both AFB and PCR. 
 
Nine cases had only one test positive: two had only AFB, two had only culture and five only 
PCR positive. The two patients with AFB-only positive both had very extensive ulcers, with 
one needing repeat excisions for secondary lesions that developed beyond the excised margins 
subsequently. One of the culture-only positive patients had an ulcer and the other a nodule. Of 
the five PCR-only positive cases, one was a large plaque in the popliteal fossa and 4 were 
ulcers; one of which – a 7-year-old lesion – was devoid of active disease.  The clinically 
easier to diagnose ulcerative lesions thus were over- rather than under-represented among the 
cases that had only one test positive. Seven (7.1%) of the 99 patients tested negative for all 
tests done; five had all 3 tests done and two (#N2 and #N3) had only AFB and culture done. 
All 7 patients were living in BU endemic communities and their lesion features, as detailed in 
Table 5, were consistent with BU.  
 
Agreement between the AFB/culture test-pair was statistically significantly higher than what 
can expected by chance (Kappa coefficient = 0.47 [standard error 0.10] and p = 0.000001). 
The coefficient was equally high for pre-ulcerative and ulcerated lesions (k = 0.42 [s.e. = 
0.13] p = 0.00008) and (k = 0.50 [s.e. = 0.13] p = 0.0001) respectively. In contrast, agreement 
for the test-pairs AFB/PCR and culture/PCR for both pre-ulcerative and ulcerated lesion 
groups were not statistically significant. We assessed the impact of lesion stage on test results, 
and found a difference in test outcomes between early and late stage lesions for culture, but 
not for AFB and PCR (Table 4). The culture positivity rate was statistically significantly 
higher for pre-ulcerative lesions than for ulcers (chi square = 4.04, p = 0.04).  Two-tests-
positive rate for pre-ulcerative lesions was significantly higher than for ulcerated lesions (Chi 
square = 4.50, p = 0.03), whereas there was no difference for one- and three-tests-positive 
rates.  
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Discussion  
The clinical diagnosis of BU is considered easy in endemic settings (1,18,19). Of cases 
clinically diagnosed in routine practice in the GWD, 93% could be reconfirmed by at least 
one of three tests performed by an in-country laboratory. The 72.3% positivity rate observed 
in our study for the IS2404 PCR was comparable to a rate of 74.8% reported by Stienstra et al. 
(12) for excised tissue samples but relatively low compared to 98% reported by Phillips et al. 
(20) for needle biopsies. The observed 78.7% culture positivity rate was comparable to our 
previous findings (17) and high, compared to previously reported rates of 39 – 55% 
(12,20,21). The AFB positivity rate of 78.1% was higher than those reported in a number of 
other studies (11,20,22).  
 
Our results with a set of samples from seven patients who had recurrences are in agreement 
with reported findings, indicating that all three laboratory tests yield false negative results 
(6,11,21,23,24). M. ulcerans bacilli are distributed unevenly in tissues (13,20,25-27) and 
inadequacy in size or site of specimen may therefore result in false negative test outcomes. In 
our study concordance between AFB/culture was statistically significant whereas concordance 
for AFB/PCR and culture/PCR was not. This may be a reflection of the different factors that 
account for false negatives of PCR as opposed to AFB and culture. In the case of the more 
sensitive IS2404 PCR test, false negative results may primarily be caused by enzyme 
inhibitory substances co-purified with the template DNA. In the case of both AFB and 
culture, false negative results are most likely to be caused by a low density of mycobacteria in 
the tissue specimen analyzed. The seven patients with all tests negative fulfilled the standard 
criteria for clinical diagnosis the same as those lesions confirmed as BU. It has to be left open 
whether clinical or laboratory diagnosis was false in these cases. Also the likelihood of false 
positive results must be considered, in particular among lesions with only one test positive. 
False positive PCRs are particularly likely to occur, due to contamination of template DNA 
with minute amounts of PCR products (11,12). Among our nine single-test-positive cases at 
least the two which were culture-only positive were unquestionably BU cases. For culture, we 
found a statistically significantly higher test positive rate for pre-ulcerative than ulcerated 
lesions. This may reflect the presence of the total load of M. ulcerans bacilli in the pre-
ulcerative situation, whereas in ulcers the bulk of bacilli may be lost along with sloughing 
necrotic tissues (21,25).  
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Laboratory diagnosis for confirmation of BU cases can either support pre-treatment decision 
making or assess the accuracy of clinical diagnosis after treatment. Both aspects are of 
increasing importance in the current situation, where antibiotic treatment is introduced and its 
efficacy needs to be assessed. For infectious diseases, culture of the causative organism is the 
most definite laboratory test. However, in the case of M. ulcerans culture takes several weeks 
and is thus impractical to aid pre-treatment diagnosis. Besides it requires a specialized 
laboratory and therefore inaccessible at the periphery. Ideally post-treatment tests should be 
done in reference laboratories in the respective endemic countries. We advocate accepting one 
positive test result in conjunction with clinical diagnosis done by well-trained clinicians as 
confirmation of BU cases. With this approach, the trade-off fraction of non-BU cases that 
would be counted as BU due to false single-test-positive results would probably be minimal, 
whereas a higher number of true BU cases would be identified. Given these considerations, 
we recommend training of peripheral level health workers to optimize clinical diagnosis of 
BU. For this, the predictive value of objective clinical features of BU must be further 
investigated. To sustain and monitor clinical diagnostic accuracy at the periphery, intermittent 
quality-control testing by in-country reference laboratories should be performed.  
 
The recent WHO recommendation to use a combination of rifampicin and streptomycin to 
support or replace surgical treatment introduces further dimensions to the dilemma of 
laboratory diagnosis of BU. The reported cure of early lesions with this treatment (14) makes 
pre-treatment confirmation imperative, as healing with antibiotics alone makes post-treatment 
diagnosis with surgically excised tissue impossible. Furthermore, accurate pre-treatment 
diagnosis is highly desirable to prevent unnecessary surgical and/or anti-mycobacterial drug 
treatment of patients with non-BU conditions. While time consuming and/or technically 
demanding methods such as culture, histopathology or PCR may be used for post-treatment 
reconfirmation at reference laboratories, rapid, inexpensive and simple laboratory tests are 
required for routine pre-treatment diagnosis at the periphery, where apart from inadequate 
resources for workspace, equipment and reagents, qualified laboratory personnel is often 
lacking. Microscopic examination of samples for AFB represents currently the most suitable 
method for rapid pre-treatment diagnosis at centers with basic local laboratory access. If only 
the AFB test is applied, it appears necessary to analyze more than one sample per lesion to 
reduce the proportion of false negative results. In cases with strong clinical diagnosis, false 
negative test results would hinder rather than assist the clinician. In the case of ulcerated 
lesions samples for AFB staining can be collected by swabbing of the undermined edges of 
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the lesion (21). In the case of pre-ulcerative lesions it is being discussed to analyze three 
needle biopsy samples per lesion for AFB. The possible complications of biopsies include 
dissemination of M. ulcerans, bleeding, secondary bacterial infection and precipitate 
ulceration of closed lesions. In addition, for small children, the procedure may be difficult and 
risky without anesthesia. Further, cultural acceptability may be problematic in areas like 
GWD with popular belief that “the needle” (injection) is contra-indicated for “boils”. 
Considering that hospital treatment is already regarded by some patients as potentially 
destructive (28), this may further reduce utilization of treatment services. Therefore 
development of diagnostic methods for BU that can be performed with blood or urine samples 
would be very helpful. Assay formats suitable for health facilities in the periphery, such as an 
agglutination or dipstick test would be preferable. Such assays are available for many 
infectious diseases and test formats could be easily adopted once a test principle suitable for 
BU has been identified. Potential test principles include the identification of M. ulcerans 
specific antigens and the detection of M. ulcerans specific immune responses. Ideally, the 
assays developed should have a high predictive value and non-technical personnel should be 
able to perform them under field conditions. In conclusion, our findings validate the 
perception that clinical diagnosis is reliable and give an indication of the degree of accuracy 
of clinical judgment achievable in routine practice in an endemic country of Africa. 
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.Table 1: Anatomical site distribution of the 108 BU lesions in the 99 patients enrolled 
Location of Lesion Male Female Total % 
Left Arm 6 10 16 14.8 
Right Arm 11 17 28 25.9 
Left Leg 15 19 34 31.5 
Right Leg 10 11 21 19.4 
Trunk 4 5 9 8.3 
Total 46 62 108 100.0 
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Table 2: Laboratory test results in seven patients with multiple recurrent lesions  
Case ID‡ Date Classification and location of lesion AFB Culture PCR 
May 8, 02 primary; plaque at abdomen + +  n. d.  
Nov 12, 02 same-site recurrence; plaque  + - n. d. 
#R1 
 
Jan 14, 03 different -site recurrence; papule at left 
thigh 
+ n. e. + 
Oct 15, 02 Primary; plaque at anterior left knee + + + 
Nov 08, 02 different - site recurrence; nodule at 
posterior right thigh 
- + - 
#R2 
 
Jan 15, 03 different - site recurrence; nodule at 
postero-lateral aspect of left thigh 
+ + + 
Nov 13, 03 Primary; nodule at right leg + + + #R3 
 Feb 11, 04 different - site recurrence; nodule at left 
foot 
- - + 
Apr 12, 02 Primary; plaque at right knee  + + + 
Mar 14, 03 same-site recurrence; ulcer (sample 1) + - - 
#R4 
 
Nov 13, 03 same-site recurrence; ulcer (sample 2) + + _ 
Mar 23, 02 Primary; plaque at left thigh + + + #R5 
 Oct 17, 02 same-site recurrence; plaque + + + 
Nov 18, 02 primary; plaque at right arm + + + #R6 
 Apr 8, 03 same-site recurrence; plaque + + + 
Apr 24, 02 primary; plaque at right arm + + - #R7 
Dec 5, 02 same-site recurrence; plaque + + + 
 
‡ Sex and age: #R1: f, 4 y; #R2: m, 3 y; #R3: m, 10 y; #R4: f, 10 y; #R5: f, 8 y; #R6: m, 23 y; 
#R7: f, 26 y; n. d. = not done; n. e. = not evaluable (contaminated culture) 
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Table 3:  Laboratory test results of 99 clinically diagnosed primary BU lesions   
Laboratory tests  Number of lesions % of lesions 
AFB +  78/99 78.8 
†Culture  + 77/97 79.4 
*PCR + 62/85 72.9 
 
AFB + and culture + 68/97 70.1 
AFB + and culture -  8/97 8.2 
AFB – and culture +  9/97 9.3 
AFB – and culture -  12/97 12.4 
Agreement# AFB/culture 80/97 82.5 
 
AFB + and PCR + 52/85 61.2 
AFB + and PCR - 16/85 18.8 
AFB - and PCR + 10/85 11.8 
AFB - and PCR - 7/85 8.2 
Agreement # AFB/PCR 59/85 69.4 
 
Culture + and PCR + 49/83 59.0 
Culture + and PCR - 16/83 19.3 
Culture – and PCR + 11/83 13.3 
Culture – and PCR - 7/83 8.4 
Agreement #  culture/PCR 56/83 67.5 
 
‡any one test pos  78/83 94.0 
‡any two tests pos  69/83 83.1 
‡all 3 tests pos  43/83 51.8 
 
† 2/99 cultures were contaminated; *PCR was not done in the case of 14/99 samples; 
#Agreement: Both tests positive, or both negative; ‡ lesions for which all three tests are 
available 
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Table 4: Effect of BU lesion stage on laboratory test results (109 tests in 99 clinically 
diagnosed patients)  
Laboratory tests  Number 
pre-
ulcerative 
lesions 
% of pre-
ulcerative 
lesions 
Number 
ulcerated 
lesions 
% of 
ulcerated 
lesions 
Total 
number 
of 
lesions 
% 
AFB +  40/52 76.9 45/57 78.9 85/109  78.0  
†Culture  +  43/50 86.0§ 39/56 69.6 82/106  77.4  
*PCR + 32/42 76.2 36/52 69.2 68/94  72.3  
 
AFB+ and culture+ 36/50 72.0 36/56 64.3 72/106 67.9 
AFB+ and culture - 2/50 4.0 7/56 12.5 9/106 8.5 
AFB - and culture+ 7/50 14.0 3/56 5.4 10/106 9.4 
AFB - and culture - 5/50 10.0 8/56 14.3 13/106 12.3 
Agreement# 
AFB/culture‡ 41/50 82.0‡2 44/56 78.6‡3 85/106 
80.2
‡ 
 
AFB+ and PCR+ 26/42 61.9 31/52 59.6 52/94 55.3 
AFB+ and PCR - 7/42 16.7 9/52 17.3 16/94 17.0 
AFB - and PCR+ 6/42 14.3 5/52 9.6 11/94 11.7 
AFB - and PCR - 3/42 7.1 5/52 9.6 8/94 8.5 
Agreement# AFB/PCR 29/42 69.0 36/52 69.2 60/94 63.8 
 
Culture+ and PCR+ 27/40 67.5 26/51 51.0 53/91 52.8 
Culture+ and PCR - 9/40 22.5 8/51 15.7 17/91 18.7 
Culture - and PCR+ 3/40 7.5 9/51 17.6 12/91 13.2 
Culture- and PCR- 1/40 2.5 6/51 11.8 7/91 7.7 
Agreement# 
culture/PCR 28/40 70.0 32/51 62.7 60/91 65.9 
 
$any one test pos, 39/40 97.5 47/51 92.2 86/91 94.5  
$any two tests pos 35/40 87.5Φ 39/51 76.5 74/91  81.3  
$all 3 tests pos 23/40 57.5 25/51 49.0 48/91  52.7  
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† 3/109 cultures were contaminated; *PCR was not done in the case of 15/109 samples; 
#Agreement: Both tests positive, or both negative; $ lesions for which all three tests are 
available;‡ Kappa coefficient : ‡1k = 0.47 [standard error 0.10] and p = 0.000001;‡2 k = 0.42 
[s.e. = 0.13] p = 0.00008;‡3 (k = 0.50 [s.e. = 0.13] p = 0.0001; §Culture positive rate pre-
ulcerative lesions compared to ulcers: chi square = 4.04, p = 0.04; Φ Two-tests-positive rate 
for pre-ulcerative lesions compared to ulcers: Chi square = 4.50, p = 0.03  
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Table  5 : Features of clinically diagnosed BU patients with all laboratory tests negative             
Case ID Age Sex Clinical form 
of lesion 
 
Key features of lesion 
#N1 
 
22 M Nodule • Patient lives in endemic community 
• Firm lesion attached to skin, but not to underlying tissues  
• Lesion near characteristic previous BU scars  
#N2 
 
15 M Nodule • Patient lives in endemic community 
• Firm lesion attached to skin, but not to underlying tissues  
#N3 
 
19 M Plaque • Patient lives in endemic community 
• Firm lesion attached to skin, not attached to underlying tissues initially, but later attached   
• Discoloration of skin overlying lesion (purplish) 
• On referral to the Korle Bu Teaching Hospital, placed on anti-TB drug treatment  
#N4 
 
9 F Ulcer • Patient lives in endemic community 
• Lesion at first a small discharging sinus, later enlarged into a typical BU  
• Necrotic slough in situ  
• Lesion near characteristic previous BU scars  
#N5 
 
65 F Ulcer • Patient lives in endemic community 
• Large ulcer with undermined edges 
• Necrotic sloughing base 
• Indurated surrounding tissues and darkened surrounding skin 
#N6 
 
2 F Ulcer • Patient lives in endemic community 
• Extensive ulcer with undermined edges 
• Necrotic slough in situ  
• Indurated surrounding tissues and darkened surrounding skin 
#N7 
 
9 M Ulcer • Patient lives in endemic community 
• Large ‘old-looking’ ulcer with signs of active disease on edges 
• Indurated surrounding tissues and darkened surrounding skin  
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Abstract 
Molecular typing methods applied so far for Mycobacterium ulcerans isolates have not 
been able to identify genetic differences among isolates from Africa. This apparent lack 
of genetic diversity among M. ulcerans isolates is indicative for a clonal population 
structure. We analysed the genetic diversity of 71 African isolates, including 57 strains 
from Ghana, by variable number of tandem repeats (VNTR) typing based on a newly 
identified polymorphic locus designated ST1 and the previously described locus, MIRU 
1. Three different genotypes were found in Ghana, demonstrating for the first time 
genetic diversity of M. ulcerans in an African country. While the ST1/MIRU 1 allele 
combination BD/BAA seems to dominate in Africa, it was only rarely found in isolates 
from Ghana, where the combination BD/B was dominating and observed in all districts 
analysed. A third variant genotype (C/BAA) was found only in the Amansie-West 
district. Results are indicative for the emergence and spreading of new genetic variants of 
M. ulcerans within Ghana and support the potential of VNTR-based typing for 
genotyping of M. ulcerans.  
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Introduction 
Mycobacterium ulcerans, the causative agent of Buruli ulcer (BU) is an emerging 
pathogen particularly in Sub-Saharan African countries, and is also found in tropical and 
sub-tropical regions of Asia, the Western Pacific and Latin America (4). BU is 
characterized by chronic, necrotic lesions of subcutaneous tissues. Due to the lack of an 
established effective antimicrobial therapy, surgical excision and skin grafting is 
currently the recommended treatment (27).  
 
While it is known that proximity to slow flowing or stagnant water bodies is a risk factor 
for M. ulcerans infection, the exact mode of transmission has remained an enigma (4). 
This is partly because no molecular typing method is available that has sufficiently high 
resolution for micro-epidemiological analyses. The apparent lack of genetic diversity of 
M. ulcerans within individual geographical regions (7, 8, 16, 19-21) is indicative for a 
clonal population structure. Genetic analyses suggest the recent divergence of 
M. ulcerans from M. marinum (5, 26), which is well known as fish pathogen and can 
cause limited granulomatous skin infections in humans (10, 11, 13). One of the hallmarks 
of the emergence of M. ulcerans as a more severe pathogen is the acquisition of a 174-kb 
plasmid bearing a cluster of genes necessary for the synthesis of the macrolide toxin 
mycolactone responsible for the massive tissue destruction seen in BU (22).  
 
Variable number of tandem repeat (VNTR) typing is a PCR-based technique identifying 
alleles of defined regions of DNA that contain a variable number of copies of short 
sequence stretches. Resolution of the method is cumulative and can be increased by 
inclusion of additional loci. Tandem repeats are easily identified from genome sequence 
data, measurement of PCR fragment sizes is relatively straightforward and VNTR typing 
data can be digitalized and compared between different laboratories. Availability of 
complete genomic sequences has facilitated identification of repetitive genetic elements 
of M. tuberculosis (12, 15, 24, 25), M. bovis (14, 18) and M. avium (6), including short 
tandem repeats designated exact tandem repeats (ETRs) and mycobacterial interspersed 
repetitive units (MIRUs). Strain typing with these sets of polymorphic loci is developing 
into an important tool in the epidemiological analysis of tuberculosis (9) and ordinary 
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agarose gel electrophoretic separation of PCR products is usually sufficient to estimate 
the number of repeat units in an allele. In a study of M. bovis strains from Chad, VNTR-
typing of a distinct number of loci is most discriminative for strains of the same clone 
(14). 
More recently, MIRUs and other VNTRs have also been described for M. ulcerans and 
M. marinum (3, 23) typing. Most of the described sequences are orthologues of the M. 
tuberculosis genome database and their resolution seems to be comparable to that of the 
currently most discriminatory methods, the 2426 PCR analysis (19) and IS2404-Mtb2 
PCR (2) which discriminate among isolates from different geographical origin, but not 
among strains from different endemic regions of Africa.  
We describe in this report a new M. ulcerans specific VNTR locus (ST1) which together 
with the previously described MIRU 1 (23) differentiated clinical isolates from Ghana 
into three VNTR allele combinations.  
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Methods  
Identification of the VNTR locus ST1 
 A tandem repeat finder software (http://www.c3.biomath.mssm.edu/trf.thml) was used to 
screen the M. marinum sequence data bank (www.sanger.ac.uk/projects/M_marinum) and 
identified a tandem repeat containing locus which was designated ST1. This locus is 
present both in M. marinum and in M. ulcerans 
(http://genopole.pasteur.fr/Mulc/BuruList.html), but not in M. tuberculosis 
(http://www.sanger.ac.uk/Projects/M_tuberculosis). A forward (ctgaggggatttcacgaccag) 
and a reverse primer (cgccacccgcggacacagtcg) located in the sequences flanking the 
identified locus and yielding a PCR product of 423 bp was designed. Genomic sequences 
corresponding to the primers were 100 % identical for M. marinum and M. ulcerans.  
 
Bacterial strains 
 A panel of 11 M. ulcerans clinical isolates of human origin from diverse geographical 
origin and of 6 M. marinum clinical isolates of human origin from Switzerland was used 
to assess the polymorphism of ST1 (Table 1). The M. marinum isolates were from 
patients living in the agglomeration of Zurich, except for M. marinum N119 that was 
isolated from a patient living in Biel. The year of isolation was 1995 for strains 853 and 
894, 1997 for strains 8972 and 946 and 1998 for strains N119 and 3023. In order to 
analyse the diversity of African M. ulcerans strains, 66 additional clinical isolates (12 
from Benin and 54 from Ghana) were included in this study. The Ghanaian strains were 
isolated (28) between 2001 and 2003 from patients being treated at the Amasaman Health 
Centre in the Greater Accra Region of Ghana (48 isolates) or the Saint Martin Hospital 
Agroyesum in the Ashanti Region of Ghana (6 isolates). The residential origin of the 
isolates is as indicated in the supporting table. 
 
DNA Extraction 
DNA was extracted as described (17). Briefly, small bacterial pellets were heated for 1 h 
at 95°C in 500 µl of an extraction mixture (50 mM Tris-HCl, 25 mM EDTA, and 5% 
monosodium glutamate). One hundred microliters of a 50-mg/ml lysozyme solution was 
then added and incubated for two hours at 37°C.  70 µl of proteinase K-10x buffer (100 
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mM Tris-HCl, 50 mM EDTA, 5% sodium dodecyl sulphate [pH 7.8]) and 10 µl of a 20-
mg/ml proteinase K solution was added. After incubation at 45°C overnight, 300 µl of 
0.1-mm-diameter zirconia beads (BioSpec Products) were added to each sample and 
vortexed at full speed for 4 min. Beads and large debris were removed by brief 
centrifugation, and the supernatants were transferred to fresh tubes for phenol-chloroform 
(Fluka) extraction. The DNA contained in the upper phase was precipitated with ethanol 
and re-suspended in 100 µl of water. 
 
PCR analysis and sequencing of PCR products 
 PCR reaction mixtures contained 1x Taq PCR buffer, deoxynucleoside triphosphates 
(0.2 mM each), 1 U of AmpliTaq Gold DNA polymerase (Perkin-Elmer Applied 
Biosystems), a 0.5 µM concentration of the primer pair and mycobacterial DNA in a final 
volume of 20 µl. Addition of 5 % DMSO to the reaction mix improved the yield of PCR 
products. The reaction was carried out using a Perkin-Elmer 9600 cycler starting with a 
denaturing step of 10 min at 95°C. After denaturation, the PCR was performed for 40 
cycles of 0.5 min at 94°C, 0.5 min at 65°C and 1 min at 72°C. The reactions were 
terminated by an incubation of 10 min at 72°C. PCR fragments were analysed by agarose 
gel electrophoresis using 2% NuSieve agarose. The size of the amplicons was estimated 
by comparison with Size Marker VIII (Roche). PCR products were directly sequenced 
with an ABI Prism 310 Genetic Analysis System. PCR products for ST1 of 423 bp and 
369 bp corresponded to a copy number of 2 and 1, respectively. For MIRU 1, copy 
numbers were assigned as described (23). 
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Results 
Identification and characterization of a new VNTR locus found in M. ulcerans and 
M. marinum  
A new VNTR locus designated ST1, was identified by screening of the M. marinum 
sequence data bank with a tandem repeat finder software. Orthologues of ST1 were found 
in M. ulcerans, but not in M. tuberculosis. Its repeat length of 54 bp is suitable for size 
analysis by standard agarose gel electrophoresis. In contrast to MIRUs (23), ST1 is not 
intergenic, but part of a pseudogene and therefore of no known functional interest 
(personal communication). When eleven M. ulcerans isolates of geographically diverse 
origin were typed by agarose gel electrophoresis of PCR products, two different alleles of 
ST1 were identified (Table 1). While eight strains had two repeats, two isolates, one from 
French Guyana and one of the two analysed isolates from Ghana had only one repeat. Of 
seven M. marinum clinical isolates tested, all five strains from patients in the 
agglomeration of Zurich (strains 8972, 946, 3023, 853 and 894) had three repeats, 
whereas strain N119 isolated from a different part of Switzerland and the reference strain 
used for the M. marinum genome sequencing project, both had two repeats. Sequence 
analysis of PCR products reconfirmed the size differences observed by agarose gel 
electrophoresis and identified six sequence variants of the repeat unit (designated A – F; 
Fig 1). Unlike many other VNTRs (1), ST1 showed no micro-deletions, but only single 
nucleotide polymorphisms (SNPs) within the sequence variants. The M. ulcerans strains 
from China and Japan turned out to have a different allele (CF; Table 1) than the other M. 
ulcerans strains with two repeats (BD). A third allele with two repeats (AC) and an allele 
with three repeats (ACE) was found in M. marinum (Table 1). Thus sequencing of ST1 
improved the discrimination power of M. ulcerans and M. marinum strains compared to 
gel electrophoresis analysis alone and revealed distinctive genotypes for M. marinum 
compared to M. ulcerans.  
 
Diversity of M. ulcerans isolates from Ghana 
Evidence for diversity of the ST1 locus in African isolates (Table 1) prompted us to 
analyse additional collections of 12 disease isolates from Benin and 54 isolates from 
Ghana (Table 2). All strains from Benin and the majority of Ghanaian strains had an ST1 
CHAPTER 5. Genetic diveristy in Mycobacterium ulcerans isolates 
 68 
allele (BD) with two repeats. However, in most strains from the Amansie West district 
(including ITM-970359; Table 1), a second allele with only one repeat (C) was identified 
(Table 2). When the Ghanaian isolates were tested also for diversity in the loci MIRU 1 
(23), VNTR 8, 9 and 19, previously described as polymorphic within M. ulcerans strains 
of different geographical origin (3), diversity was also found in locus MIRU 1. Sequence 
analysis of PCR products of selected strains reconfirmed the size differences observed by 
agarose gel electrophoresis and identified two sequence variants of the MIRU 1 repeat 
unit (designated A and B; Fig 1).  
Altogether three VNTR allele combinations were found among the clinical isolates from 
Ghana (Table 2, Fig. 2 and 3). While all isolates from the Ga, Akwapim South, Ahafo-
Ano North and Akim Abuakwa districts had the ST1/MIRU 1 allele combination 1 
(BD/B), two allele combinations, i.e. 1 and 2 (C/BAA) were found among the five 
isolates from the Amansie-West district. A third allele combination (BD/BAA) was found 
in two strains (Agy99 from the Ga district and ITM 97-0359 from the Ashanti region) 
isolated before 2000 in Ghana and in all other African isolates.  
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Discussion 
Molecular typing methods such as multi-locus sequence typing, 16S rRNA sequencing, 
restriction fragment length polymorphism and variable number of tandem repeats typing 
have revealed a remarkable lack of genetic diversity of M. ulcerans and a clonal 
population structure within given geographical regions. The discriminatory power of all 
these methods is particularly insufficient to differentiate between African isolates. 
Innovative molecular genetic fingerprinting methods are therefore required for local 
epidemiological studies aiming to reveal transmission pathways and environmental 
reservoirs of M. ulcerans. First attempts to use VNTR typing for M. ulcerans (3, 23) have 
identified variable loci suitable for discrimination of disease isolates at continental level. 
In this study we used a newly identified (ST1) and four previously described VNTRs to 
analyse genetic diversity within a collection of 71 M. ulcerans strains from Africa, 
including 57 isolates from Ghana. Three of the previously described VNTRs i.e. VNTR 
8, 9 and 19 (3) were not able to discriminate among the African strains. Yet MIRU 1 (23) 
and the newly identified locus (ST1) defined three subgroups within the Ghanaian strains.  
 
The fact that two allele combinations (BD/B and C/BAA) differing from the common 
African combination (BD/BAA) were found within a recent (2001-2003) collection of 
Ghanaian isolates is indicative for an ongoing microevolution of M. ulcerans and for the 
spreading of new variants within Ghana. It is tempting to hypothesize that allele 
combination 3 (BD/BAA) represents an ancestral like genotype and that the others 
evolved by reduction in the repeat unit numbers in the ST1 locus (from BD to C) or in the 
MIRU 1 locus (from BAA to B), respectively. While conversion of the MIRU 1 locus 
from BAA to B could be explained by deletion of the two A repeat units, conversion of 
the ST1 locus from BD to C by a deletional mechanism would require that a central 
sequence stretch of the BD repeat region comprising portions of both the B and the D 
repeat unit would have been lost, yielding the hybrid repeat unit C. 
 
While allele combination 3 seems to be the most common in Africa, most of the M. 
ulcerans strains from Ghana analysed, had the allele combination 1. This genotype was 
found in all Ghanaian districts included in this study. Allele combination 2 dominated in 
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the Amansie West district, but was found exclusively there. Follow up of the temporal 
and spatial patterns of emergence and spreading of genotypes may contribute in future to 
our understanding of the transmission and epidemiology of Buruli ulcer. From the present 
data, we cannot draw any conclusions why certain variant appear to be the more 
successful than others. The fact, that we were not able to sub-group the 47 isolates from 
the Ga district by VNTR (with the only exception of the ‘older’ isolate Agy99) 
reconfirms that M. ulcerans has a clonal population structure associated with a low rate 
of genomic drift. Availability of the fully assembled and annotated genome sequence of 
M. ulcerans in the near future will facilitate identification of further polymorphic VNTR 
loci potentially contributing to further refinement of genetic fingerprinting of M. ulcerans 
isolates.  
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Species Isolate Country of 
origin 
Number of 
repeats 
Arrangement of the variant 
repeat DNA sequences 
M. ulcerans 
 
ITM 8756 
ITM 980912 
ITM 941328 
ITM 884 
ITM 9357 
ITM 7922 
ITM 970359+ 
ITM 970321 
ITM 940886 
ITM 940662 
ITM 960658 
Japan 
China 
Malaysia 
Australia 
PNG 
French Guyana 
Ghana 
Ghana 
Benin 
Côte d'Ivoire 
Angola 
2 
2 
2 
2 
2 
1 
1 
2 
2 
2 
2 
C F 
C F 
B D 
B D 
B D 
C 
C 
B D 
B D 
B D 
B D 
M. marinum 
 
894/1995 
853/1995 
8972/1997 
946/1997 
3023/1998 
N119/1998 
M. marinum* 
Switzerland 
Switzerland 
Switzerland 
Switzerland 
Switzerland 
Switzerland 
unknown 
3 
3 
3 
3 
3 
2 
2 
A C E 
NOT DONE 
NOT DONE 
NOT DONE 
NOT DONE 
NOT DONE 
A C 
 
Table 1: ST1 alleles of M. ulcerans and M. marinum disease isolates 
*isolate used for the M. marinum genome sequencing project 
+isolated in 1997 from a patient living in the Amansie West district 
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Country of 
origin 
District Number 
of strains ST1 allele MIRU 1 allele 
Allele 
combination 
Ga district 47 2 (BD) 1 (B) 1 
Ga district 1 2 (BD) 3 (BAA) 3 
Akwapim South 1 2 (BD) 1 (B) 1 
Akim Abuakwa 1 2 (BD) 1 (B) 1 
Ahafo-Ano  1 2 (BD) 1 (B) 1 
Amansie West  1 2 (BD) 1 (B) 1 
Amansie West  4 1 (C ) 3 (BAA) 2 
Ghana 
unknown○ 1 2 (BD) 3 (BAA) 3 
Benin  13 2 (BD) + 3* (BAA)+ 3 
Côte d'Ivoire  1 2 (BD) 3* 3 
Angola   1 2 (BD) 3* 3 
 
Table 2: ST1 and MIRU 1 allele combinations of M. ulcerans strains from Africa 
VNTR copy numbers for ST1 and MIRU 1 were determined and allele combinations 
assigned (1-3). Sequence profiles of M. ulcerans strains are shown in brackets. ○isolated 
at the Saint Martin’s hospital in the Ashanti region; * MIRU 1 copy numbers as 
previously described (23); +only one strain (ITM 94-0886) was analysed by sequencing 
(23). 
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Allele ST1 repeat unit sequences 
A CCGGTTCTGTTTCGTCCGGTGCGACCGCTGGCACTGTCTCGACCGGTGCGA
CGA 
B .........................................G....C....
... 
C .........................................G.........
..G 
D .......G...G.C...........................G.........
..G 
E -
T.....G...G.C...........................G..........
.G 
F .......G...G.C....A......................G.........
..G 
 
Allele MIRU 1 repeat unit sequences 
A* ATGAGCCAGCCGGCGACGATGCAGAGCGAAGCGATGAGGAGGAGCGGCGCC
AG    
B G...A..C..T........................................
.. 
 
Figure 1: Sequence variation of ST1 and MIRU 1 tandem repeat units  
 (-): Base deletions; (.): identical sequence positions.  
*Allele A of MIRU 1 corresponds to variant A2 (23). 
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Figure 2: Map of southern Ghana showing the residential districts of patients from 
whom the Ghanaian isolates analysed in this study were obtained 
ST1/MIRU 1 allele combinations are genotype 1: BD/B, genotype 2: C/BAA and 
genotype 3: BD/BAA. 
 
 
 
 
Figure 3: Agarose gel electrophoretic analysis of PCR products from amplifications 
with MIRU 1 primers (upper Panel) and STI primers (lower panel) 
Results with selected isolates are shown. 1: strain (Amansie-West district); 2: strain 
(Amansie-West district); 3: strain (Ga district); 4: strain (Ga district); 5: strain (Ga 
district); 6: strain (Amansie-West district); 
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 Abstract 
Buruli ulcer caused by Mycobacterium ulcerans is of important public health problem 
especially in West-Africa. It is the third most common mycobacterial disease, after 
tuberculosis and leprosy. The World Health Organisation currently recommends the use 
of a combination of streptomycin and rifampicin for eight weeks before surgical excision. 
Stepwise implementation of this recommendation has started in some of the worst 
affected West African countries, including Ghana. Therefore this study was initiated to 
assess the susceptibility of M. ulcerans isolates from Ghana to isoniazid, rifampicin, 
ethambutol and streptomycin, using a microplate Alamar blue assay.  Out of the 28 
isolates tested, one was resistant to all four drugs analysed. All isolates with the exception 
of two (7.1%) and three (10.7%) were resistant to isoniazid and ethambutol respectively.  
On the contrary all isolates, except two (7.1%) and three (10.7%), were susceptible to 
rifampicin and streptomycin, respectively. This first report of rifampicin resistance in 
clinical M. ulcerans isolates raises major concern about antibiotic treatment modalities 
for Buruli ulcer. 
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Introduction 
Buruli ulcer, caused by M. ulcerans disease is increasingly becoming an important public 
health problem in the tropics especially in West-Africa with thousands of reported cases 
(1). While it is the third most common mycobacterial disease in the world, in some of the 
worst affected communities in this region, it is the leading mycobacterial disease. In 
some villages in West Africa, the disease affects more than 20% of the inhabitants (2). 
Most of the patients are poor rural dwellers and about 70% of the affected are children 
under the age of 15 years with limited access to health services (2,3). A number of social 
issues such as fear of anaesthesia and surgery, distance to health centre with surgical 
facilities, economic burden on families due to the long stay in hospitals delays health 
seeking (3,4). Due to this majority of patients in endemic communities in Africa presents 
with extensive lesions that cause severe disabilities (3).  Various studies estimates that 
between 25 and 66% persons healed of ulcers had chronic functional disabilities (2,5).  
 
The standard treatment of BU is surgical excision followed by skin grafting, because the 
available antimycobacterial compounds have been considered ineffective. The main 
objective of treatment in Buruli ulcer is to stop the progression of infection and healing of 
lesions (2). Surgical treatment requires wide excision including margins of healthy tissue 
to prevent relapse due to subcutaneous infection from left over bacilli. In addition, it is 
not always successful, and relapse rates between 6-47% have been reported (2,6,7).   
 
A combinational treatment with aminoglycosides and rifampicin has shown good efficacy 
in M. ulcerans infection animal model studies (8,9). Supported by results of a clinical 
trial in Ghana (10) and ongoing clinical studies in several countries, the current WHO 
guidelines, require that a patient is treated with a combination of rifampicin and 
streptomycin for 8 weeks before surgery. This is expected to reduce the indication for 
surgery, extent of surgery and relapse rates. Surveillance of drug resistance in endemic 
countries is essential to determine the existing level and nature of the drug resistance 
problem.  
 
CHAPTER 6. Streptomycin and rifampicin resistant isolate 
 82 
The commonly used agar proportion method for mycobacterial antibiotic susceptibility 
testing requires 8 weeks of incubation before a pattern of susceptibility is established for 
M. ulcerans (11).  The duration of the assay can be shortened by the use of the BACTEC 
radiometric system to around 10 days (12). However the BACTEC method is expensive 
and uses radioactivity, which makes is out reach for endemic countries with limited 
resources. The ability to detect mycobacterial growth by identification of the colour 
changes associated with the reduction of nitrate to nitrite is the basis for the microplate 
Alamar Blue drug susceptibility assay (MABA). MABA has been used previously in 
drug-susceptibility testing of M. tuberculosis to antituberculosis drugs. Very good 
correlations with the proportional and BACTEC methods have been described (13,14). 
Alamar blue is a resarzurin-based oxidation-reduction indicator which measures 
colorimetric drug MICs for M. tuberculosis for up to 7 days. MICs are determined by 
using serial dilutions of anti-TB drugs in 96-well microtiter plates, broth, and M. 
tuberculosis isolates. It is also less expensive, simpler to execute than the proportion 
method, and has a high through-put. This study had two objectives: i) to adapt the MABA 
assay for M. ulcerans and ii) to use this method to evaluate the susceptibility of M. 
ulcerans isolates to the recommended WHO antimycobacterial agents for treatment.  
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Materials and Methods 
Mycobacterial isolates: Seven mycobacterial isolates obtained from pulmonary TB 
patients attending a teaching hospital in Ghana were used for the establishment of the 
MABA assay in our laboratory. Of the seven isolates, six were identified as belonging to 
the M. tuberculosis complex (MTC) and one was MOTT by conventional biochemical 
assays-niacin production, nitrate reduction and sensitivity to thiophen-2-carboxylic acid 
hydrazide and p-nitrobenzoic acid. The drug susceptibility patterns of all seven isolates to 
rifampicin, isoniazid, streptomycin and ethambutol have already been tested with the 
standard proportional method (15). This was used as the gold standard procedure for the 
establishment of the microplate Alamar blue assay (MABA). 
Twenty-eight strains of M. ulcerans analyzed in this study came from a collection of M. 
ulcerans isolates generated in our laboratory between 2001 and 2005 (table 1). 
Preliminary identification of isolates was done by analyzing the rate of growth, colonial 
morphology and acid-fastness by the ZN staining. All isolates were confirmed by the 
presence of the insertion sequence IS2404 in a PCR reaction (16).  
 
Preparation of bacterial suspension for MABA: Mycobacterial isolates used were first 
subcultured on LJ medium and incubated at 37°C and 31°C for M tuberculosis and M. 
ulcerans respectively.  Mycobacterial suspensions were prepared by emulsify 2-3 loops 
of logarithmic growing mycobacteria with 0.5ml 7H9 medium supplemented with OADC 
and 0.05% tween 80 (7H9-T) in a screw capped tube containing eight glass beads. After 
dispersing the bacteria by minimal vortexing, the clumps in the suspension were allowed 
to settle for a while and the supernatant was transferred to a new tube. The turbidity of 
the supernatant was adjusted to McFarland 1 with 7H9 broth supplemented with casitone 
and OADC (7H9GC). In the case of M. ulcerans, the supernatant was passed through a 
filter of 0.8µm pore size to obtain a uniform suspension. This was diluted further by 1:25 
for the MABA assay.  
 
Drug Solutions: Rifampicin (RIF), isoniazid (INH) and streptomycin (STR) were 
purchased from Sigma Chemicals whilst ethambutol (EMB) was obtained from Aldrich-
Fluka. Stock solutions of INH, EMB and STR were made by dissolving the powder in 
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deionised water, whilst that of rifampin was in dimethyl sulphoxide. After sterilising by 
filtration, the stocks were then divided into 1-ml aliquots and frozen at -70C. The stock 
solutions were thawed, and working dilutions were made by diluting the stock solution in 
7H9GC medium. Fresh dilutions were made on each day that testing was performed. 
 
Susceptibility testing with MABA: The MICs of each antibiotic were determined for 
each isolate. MABA susceptibility testing was performed according to the method of 
Franzblau et al (17) and Luna-Herrera et al (14) with slight modifications. Briefly serial 
dilutions of the tested drugs were made in a 96 well plate (falcon 3072), using the 
culturing broth as the diluent. We compared the performance of 7H9GC to 7H9-T, results 
of assays with 7H9GC were always a day or two ahead of 7H9-T and hence we used the 
former through out this study. The final drug concentration ranges were 2-0.062µg/ml; 1-
0.031 µg/ml; 4-0.125µg/ml & 16-0.5µg/ml for RIF, INH, STR and EMB respectively. 
Then each test well was inoculated with 100µl of bacterial suspension of about 104 
colony forming units. The plate was then covered with its cover and placed in sealable 
polyethylene bag before incubating at appropriate temperatures (37°C for TB isolates and 
31°C for M. ulcerans isolates). For the TB isolates assays were read each morning on 
days 6-9 while for the M. ulcerans, it was read on day 7 and each other day, until day 17.  
The assays were read for colour change by visual examination by at least two people 
blindly for each assay. The colour change of the test sample was compared to that of a 
1% mycobacterial suspension control well and the MIC was defined as the lowest 
concentration with a comparable blue colour as this control well. 
 
Proportion Method: We repeated the susceptibility testing for all M. ulcerans isolates 
which showed resistance to rifampicin and or streptomycin by the indirect proportion 
method using the critical concentrations of 40 mg/ml for rifampin, 0.2 mg/ml for 
isoniazid (INH), 4 mg/ml for streptomycin, and 2 mg/ml for ethambutol. An isolate was 
considered susceptible to an anti-mycobacterial agent if the number of colonies that grew 
on the drug containing plate was < 1% of the number of colonies that grew on the drug-
free control, intermediate resistance if the proportion is between 1 and 10%, and resistant 
if the proportion is > than 10% (18,19).  
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Results 
Agreement between MABA and agar proportion method: Table 2 summarizes the 
results of the in vitro susceptibility of seven TB isolates using the proportion and MABA 
procedures.  Of the seven isolates from TB patients, all six MTC strains were susceptible 
to rifampicin, while the MOTT strain was resistant in the proportion method. All the 
seven isolates were susceptible by the MABA procedure and the MIC was ≤0.062µg/ml. 
We repeated both procedures for the isolate (K91) with the discordant result; the result 
remained the same for both methodologies. It was again resistant by the proportion 
method and the MIC determined by MABA became 0.125µg/ml, higher compared to the 
previous value of ≤ 0.062µg/ml. Thus from our study the agreement between the two 
methods for the determination of susceptibility to rifampicin was 85.7%.  
 
Four of the TB isolates were susceptible and the remaining three were found to be 
resistant by the agar proportion method to isoniazid. When we analyzed the isolates by 
MABA, all four susceptible strains had a MIC ≤ 0.031µg/ml. For the resistant isolates 
two had MIC>1µg/ml and the remaining had 0.5µg/ml.  We repeated the isolate with the 
MIC of 0.5µg/ml and obtained the same result. Using the parameters by Yajko et al, (20) 
this was described as intermediate.  For five of the streptomycin susceptible isolates by 
the proportion method, the MIC using MABA was between 0.125µg/ml and 0.25µg/ml. 
The MIC of the two resistant isolates was >4µg/ml. The agreement between the two 
methods for the analysis of in vitro activity of streptomycin against the TB isolates was 
100%. All isolates tested were susceptible to ethambutol using the two methods. MICs as 
determined by MABA ranged between <0.5 and 4µg/ml. Five of the isolates had MIC of 
1µg/ml, one had 0.5µg/ml and the remaining had 4µg/ml. Thus among the 28 individual 
susceptibility assays done with the seven isolates only two discordant result were found 
(Table 2). Hence the overall agreement between these methods was 92.8%.  
 
Drug susceptibility pattern of M. ulcerans isolates: All 28 clinical M.  ulcerans isolates 
from Ghana were susceptible to rifampicin with the exception of two isolates (NM050/05 
and NM038/04). One of the strains was from Ga district and the other from the Amansie-
West district respectively. The later was resistant to all the drugs tested. Most of the 
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isolates were resistant to INH (82.1%); two were susceptible whilst three had 
intermediate susceptibility. Out of the 28 isolates, 3 (10.7%) were susceptible, 1 (3.6) 
intermediate and 24 (85.7%) were resistant to ethambutol. 25 (89.2%) were susceptible, 2 
(7.2%) were intermediate and 1(3.6%) was resistant to streptomycin.  Thus out of the 28 
isolates, 1 was resistant (3.6%) to all drugs, 1 susceptible (3.6%) to all drugs and the 
remaining were resistant to at least one drug. Majority (71.4%) were not susceptible to 
both isoniazid and ethambutol, and this we considered as having the normal pattern. 
When we compared the spectrum of antibiotics-resistance to VNTR genotypes (26), all 
the STR and RIF resistance strains had genotype 1. 
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Discussion 
Conventionally the drug susceptibility pattern of mycobacterium species is determined by 
comparing the number of colonies that grow on a plate/tube of drug containing medium 
with the number of colonies that grow on a drug free control medium (21). Unfortunately 
this method is limited as a result of the time required to obtain the end result. With the 
slow growing M. ulcerans, it takes about eight weeks to establish a susceptibility pattern 
(11). In addition it is labour intensive. Several rapid methods have been established for 
susceptibility testing in M. tuberculosis. These methods include: 1) detection of 
mutations in specific genetic markers (22) 2) flow cytometric analysis (23) and 3) 
BACTEC radiometric analysis (12). These methods are also limited for use in developing 
countries as the reagents are expensive and also require elaborate infrastructure. In this 
study we adapted the microplate Alamar blue assay for the determination of drug 
susceptibility of M. ulcerans isolates. Findings from the assays confirmed the rapidity of 
the assay and had a good correlation with the agar proportion method (14). It took 10 
days to obtain the results of 70%, 14 days for almost 90% and 21 days for 100% of the 28 
strains tested. The advantage of this assay is its simplicity in terms of infrastructure 
requirement as MICs were established visually. 
 
With the exception of two and three isolates, all the isolates tested were resistant to 
isoniazid and ethambutol respectively and this finding is comparable with previous data. 
The phenotypic analysis of M. ulcerans isolates from different endemic regions revealed 
that about 80%  of the African isolates were resistant to isoniazid (24). Also in vitro 
susceptibility studies showed that M. ulcerans is highly resistant to ethambutol (25). In 
contrast only two and three isolates were not susceptible to rifampicin and streptomycin 
respectively. This finding raises major concern regarding the recommended combination 
treatment of BU patients with rifampicin and streptomycin for eight weeks before 
surgical excision. This recommendation has not yet been established fully in most of the 
endemic countries. The identification of resistant strains in Ghana, which is one of the 
worst affected countries, represents a great threat to this recommendation. A major 
consideration is, that rifampicin and streptomycin are effective antituberculosis drugs. 
Incidentally, all the worst affected countries are endemic for tuberculosis and the above 
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antibiotics are essential for their respective DOTS programs. Most BU patients carry high 
bacterial burden at some stage of the disease, which is very crucial for the selection of 
drug resistant mutants. Furthermore, BU is a tropical disease that occurs normally in 
children and streptomycin has side effects in growing children when exposed to the sun. 
With the limited number of strains and different BU foci included in this study, the 
analysis must be expanded with isolates from other foci to establish the depth of the 
problem. 
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Facility ID 
Year 
Isolates Age Sex 
District 
Of Origin Patient Class 
Site Of 
Lesion 
Type Of 
Lesion 
AHC NM012/01 2001 19 M Ga Recurrent Lower limb Nodule 
AHC NM014/01 2001 21 M Ga New Abdomen Ulcer 
AHC NM018/02 2002 39 F Ga New Upper limb Nodule 
AHC NM023/02 2002 10 F Ga New Lower limb Plaque 
AHC NM027/02 2002 26 F Ga New Upper limb Plaque 
AHC NM028/02 2002 4 M Ga New Upper limb Nodule 
AHC NM030/02 2002 10 F Ga New Upper limb Plaque 
AHC NM031/02 2002 16 F Ga New Upper limb Plaque 
AHC NM033/02 2002 10 F Ga New Lower limb Nodule 
AHC NM037/02 2002 38 F Ga New Upper limb plaque 
AHC NM038/02 2002 11 F Ga Recurrent Upper limb Nodule 
AHC NM040/02 2002 75 M Ga New Upper limb Plaque 
AHC NM050/02 2002 8 M Ga New Lower limb Ulcer 
AHC NM051/02 2002 9 F Ga Recurrent Lower limb nodule 
AHC NM049/05 2005 40 M Ga New Lower limb
 
nodule 
AHC NM050/05 2005 10 F Ga New Lower limb Ulcer 
AHC NM051/05 2005 4 M Ga New Upper limb ulcer 
AHC NM053/05 2005 4 M Ga New Lower limb plaque 
AHC NM054/05 2005 17 M Ga New Upper limb ulcer 
AHC NM057/05 2005 16 F Ga new Lower limb ulcer 
AHC NMO59/05 2005 4 M Ga New Upper limb ulcer 
AHC NM061/05 2005 4 M Ga New Abdomen Nodule 
AHC NM063/05 2005 3 M Ga New Upper limb Ulcer 
AHC NM065/05 2005 41 F Ga New Lower limb Ulcer 
SMH NM022/04 2004 7 F AW New Neck plaque 
SMH NM031/04 2004 12 F AW New Upper limb Nodule 
   SMH NM037/04 2004 17 F AAN New Lower limb Nodule 
SMH NM038/04 2004 5 F AW new Lower limb Plaque 
Table 1: the clinical isolates we used in this study. AHC=Amasaman Health Centre, 
SMH= Saint Martin Hospital, Agroyesum, AW=Amansie West and AAN=Ahafo-Ano 
North  
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Table 2: Susceptibility pattern of clinical pulmonary tuberculosis’ isolates using the 
microplate alamar blue assay (MABA) and the indirect proportional method. The MIC 
values were obtained from the MABA assay. 
S= Sensitive, R= Resistance 
 
 
 
 
 
 
Isolate MIC (µg/ml) MABA Proportional Method 
 RIF INH STR EMB RIF INH STR EMB RIF INH STR EMB 
KB1 ≤0.062 >1 >4 1 S R R S S R R S 
K3 ≤0.062 ≤0.031 ≤0.125 1 S S S S S S S S 
K4 ≤0.062 ≤0.031 ≤0.125 0.5 S S S S S S S S 
K6 ≤0.062 ≤0.031 ≤0.125 1 S S S S S S S S 
K68 ≤0.062 ≤0.031 0.25 1 S S S S S S S S 
K91 ≤0.062 >1 >4 4 S R R S R R R S 
K97 ≤0.062 0.5 0.25 1 S I S S S R S S 
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SUSCEPTIBILITY 
ID RIF INH STR EMB 
NM012/01 S R I R 
NM014/01 S R S R 
NM018/02 S R S R 
NM023/02 S R S R 
NM027/02 S R S R 
NM028/02 S R S R 
NM030/02 S R S R 
NM031/02 S R S R 
NM033/02 S R S R 
NM037/02 S R S R 
NM038/02 S R S R 
NM040/02 S R S S 
NM050/02 S I S I 
NM051/02 S R S R 
NM049/04 S R S R 
NM050/05 R I S S 
NM051/05 S I I R 
NM053/05 S R S R 
NM054/05 S R S R 
NM057/05 S S S R 
NMO59/05 S R S R 
NM061/05 S R S R 
NM063/05 S R S R 
NM065/05 S S S S 
NM022/04 S R S R 
NM031/04 S R S R 
NM037/04 S R S R 
NM038/04 R R R R 
 
 Table 3: Results of susceptibility tests for 26 isolates of Mycobacterium 
tuberculosis exposed to isoniazid (INH), rifampicin (RIF) and ethambutol 
(EMB) by microplate alamar blue assay. 
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Abstract 
Buruli ulcer (BU), caused by Mycobacterium ulcerans, is the third most common 
mycobacterial infection in immuno-competent humans besides tuberculosis and leprosy. 
We have compared by ex vivo ELISpot analysis interferon-gamma (INF-γ) responses in 
peripheral blood mononuclear cells (PBMC) from BU patients, house-hold contacts and 
individuals living in an adjacent M. ulcerans non-endemic region. PBMC were 
stimulated with PPD and non-mycobacterial antigens like reconstituted influenza virus 
particles and isopentenyl-pyrophosphate. With all three antigens the number of INF-γ 
spot forming units was significantly reduced in BU patients compared to the controls 
from a non-endemic area. This demonstrates for the first time that M. ulcerans infection-
associated systemic reduction in INF-γ responses is not confined to stimulation with live 
or dead mycobacteria and their products, but extends to other antigens. IL-12 secretion by 
PPD stimulated PBMC was not reduced in BU patients, indicating that reduction in INF-γ 
responses was not caused by diminished IL-12 production. Several months after surgical 
excision of BU lesions, INF-γ responses of BU patients against all antigens used for 
stimulation recovered significantly, indicating that the measured systemic immuno-
suppression was not the consequence of a genetic defect in T cell function predisposing 
for BU but is rather related to the presence of M. ulcerans bacteria.   
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Introduction 
BU caused by M. ulcerans is an infectious disease characterized by chronic, necrotizing 
ulceration of subcutaneous tissues and the overlying skin. The disease starts as a 
subcutaneous nodule, papule or plaque that eventually ulcerates and progresses over 
weeks to months until surgical excision or spontaneous healing occurs [1]. After 
tuberculosis and leprosy BU is the third most common mycobacterial infection in 
immuno-competent humans [2]. The main burden of disease falls on children living in 
sub-Saharan Africa but healthy people of all ages, races and socio-economic class are 
susceptible [3]. The effectiveness of anti-mycobacterial drug therapy has not been proven 
[3]. Consequently, surgery is presently the recommended treatment option [4]. In BU 
lesions clumps of extra-cellular acid-fast organisms surrounded by areas of necrosis are 
found particularly in subcutaneous fat tissue [5]. M. ulcerans produces a family of 
macrolide toxin molecules, the mycolactones, which are associated with tissue 
destruction and local immunosuppression [6]. In cell culture experiments mycolactones 
produce apoptosis and necrosis in many human cell types [7;8]. The toxin appears to play 
a role in inhibiting the recruitment of inflammatory cells to the site of infection, which 
explains at least in part why inflammatory responses are poor in BU lesions [5]. 
However, intra-lesional influx of leukocytes and granulomatous responses in the dermis 
and panniculus has been reported in late stages of the disease [9] [10]. Spontaneous 
healing can occur and is often accompanied by a conversion of the Burulin (M. ulcerans 
sonicate) skin test from negative to positive. However, the immune mechanisms involved 
in protection against BU are largely unknown. 
 
The importance of INF-γ for immunity against mycobacterial infections in humans is 
demonstrated by the increased susceptibility of children carrying complete INF-γR1 
chain deficiency to environmental mycobacterial infection [11]. Apart from CD4+ T cells, 
γδ T cells, natural killer cells and CD8+ T cells are potent sources of IFN-γ. CD4 T cells 
can be differentiated into Th1 and Th2, distinguished by their patterns of cytokine 
production after antigen activation. Apart from other cytokines, Th1 cells preferentially 
secrete INF-γ, while Th2 cells preferentially secrete IL-4 and IL-5. Th1 or Th2 
development is determined by the cytokine environment during T cell activation in the 
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primary response to antigen with IL-12 and INF-γ implicated in the decision to adopt a 
Th1 phenotype [12]. INF-γ binds to the INF-γR1/INF-γR2 receptor complex and 
stimulates innate cell-mediated immunity through NK cells and activation of bactericidal 
mechanisms in macrophages. The central role of INF-γ in MHC class I and class II 
restricted antigen processing and presentation is well documented [13]. At present, the 
contribution of INF-γ in immunity to extra-cellular M. ulcerans remains to be established.  
 
Peripheral blood mononuclear cells (PBMC) of BU patients with active disease showed 
significantly reduced lympho-proliferation and INF-γ secretion in response to stimulation 
with live or killed preparations of M. bovis, M. ulcerans, M. tuberculosis and the 
recombinant protein Ag85 of M. tuberculosis [14-18]. Here we have determined in a 
cross-sectional study the frequency of INF-γ secreting cells in PBMC from BU patients, 
their household contacts and controls from BU non-endemic areas by ex vivo ELISpot 
analysis. The antigens used for stimulation included isopentenyl-pyrophosphate (IPP), 
reconstituted influenza virus particles (virosomes) and tuberculin purified protein 
derivative (PPD) of M. tuberculosis, which stimulate distinct T cell subsets, like Vγ2Vδ2 
T cells [19], CD4 T cells [20], CD4 and Vγ2Vδ2 T cells [21], respectively. Results 
demonstrate that BU associated reductions in INF-γ responses are not confined to 
stimulation with live or dead mycobacteria and mycobacterial antigens. Furthermore, it is 
shown for the first time that in individual BU patients this suppression in INF-γ secretion 
improved in a time interval of 5 to 10 months.  
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Materials and Methods 
Study population 
Thirteen BU patients, 19 clinically healthy household contacts that never had clinical BU 
and 18 healthy persons living in a M. ulcerans non-endemic districts in the Greater Accra 
region of Ghana were enrolled for the study (Table I). All BU patients enrolled were 
residents of the BU-endemic Ga District and presented with pre-ulcerative or ulcerative 
lesions at the Amasaman Health Centre. Informed consent was obtained from study 
participants or their parents or guardians before enrollment. For ethical reasons, the age 
range of the non-exposed controls that were included into the analysis was higher than 
that of the BU patients. Ethical approval for the study was obtained from the local ethical 
review board of the Noguchi Memorial Institute for Medical Research, University of 
Ghana, Legon. Clinical diagnosis of BU was reconfirmed as described [22;23] by one or 
more laboratory verification tests (Table II) including culture of M. ulcerans, microscopic 
detection of Acid Fast Bacilli (AFB) or IS2404 PCR. The clinical pictures of the patients 
ranged from nodules or plaques to severe ulcerative forms (Table II). In the BU group 
nine persons and in the other two groups each 10 persons with a BCG scar were recruited 
(Table I). PBMC were isolated from venous peripheral blood using Ficoll-Hypaque 
gradient centrifugation following standard procedures and cryo-preserved prior to the 
analysis.  
 
Antigens 
After thawing PBMC were directly stimulated with 50 µM isopentenyl pyrophosphate 
(IPP; Sigma), 10 µg/ml tuberculin purified protein derivative of M. tuberculosis (PPD; 
Statens Seruminstitut, Denmark), 10 µg/ml PHA (Sigma) or 20 µg/ml reconstituted 
influenza virus particles (IRIV, Berna Biotech). These influenza virosomes are spherical 
uni-lamellar vesicles prepared by detergent removal from influenza surface glycoproteins 
and mixtures of natural and synthetic phospholipids containing H1N1 from influenza 
virus strain A/Singapore/6/86 [24]. Cell culture medium consisted of RPMI 1640, 10 % 
heat inactivated human AB serum, 2 mM glutamine, 100 U/ml penicillin, 100 µg/ml 
streptomycin (Gibco-BRL). 
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Ex vivo INF-γ ELISpot análisis 
PBMC were thawed, washed and suspended at a concentration of 2 x 106 cells/ml in 
complete cell culture medium. The cells were then stimulated with the different antigens 
at the final concentrations indicated above and incubated for 24 h at 37°C, 5 % CO2 
humidified atmosphere. A 96-well nitrocellulose-bottomed plate (Millipore) was coated 
overnight at 4°C with 10µg/ml anti-human-INFγ primary antibody (clone1-D1K; 
Mabtech, Sweden). The plates were then washed five times with PBS and blocked with 
cell culture medium for 1 h at room temperature. The medium was decanted and pre-
incubated cells (2 x 105 or 1 x 105) were added to each well in triplicate and incubated at 
37 °C for another 20 h. Assays were terminated by washing plates three times with PBS-
Tween 80 (0.05 %) followed by PBS another three times. Secondary antibody (biotin-
labeled anti-human-INF-γ; clone 7-B6-1) was added to each well at 1µg/ml and the plate 
incubated for 2 h at RT. Plates were washed again six times with PBS before application 
of streptavidine-alkaline phosphatase (1 : 1000 dilution in PBS, 0,5 % FCS, 100 µl/well) 
for 1 h at RT. After washing wells seven times with PBS, distinct spots were developed 
by the incubation of plates at RT for 4 to 10 min following the addition of the developing 
buffer (BCIP/NBT, diluted 1 : 100, Bio-Rad). Spot development was stopped by washing 
the plates extensively with water and left to dry. Plates were later evaluated using the 
ELISpot Reader system (AID, Germany) to determine the number of spot forming units 
(SFU).  
 
ELISA quantification of IL-12 in cell culture supernatants 
 Levels of total IL-12 in culture supernatant of PBMC incubated with PHA (10 µg/ml) 
and PPD (10 µg/ml) for 96 h were determined by ELISA employing a commercial kit 
(Mabtech, Sweden). Samples were analyzed in triplicates and results expressed as the 
average of the three readings in an ELISA reader at 450 nm with reference to curves 
generated using serially diluted recombinant human IL-12. The sensitivity of the assay 
was 30 pg/ml for total IL-12.  
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Statistical analysis 
 Data were analyzed using the STATA program (Stata Corporation). Comparisons among 
the paired samples were performed using the Wilcoxon signed-rank test whilst the 
wilcoxon rank-sum test was used to analyze the significance of observed difference in IL-
12 secretion between patients and un-exposed controls. For comparing the frequencies of 
antigen specific IFN-γ secreting cells, the data was transformed to normality using Box-
Cox transformation before analyzed by linear regression. Data were considered 
statistically significant when P< 0.05. 
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Results 
Frequency reduction of INF-γ secreting spot forming units in PBMC from BU 
patients 
 Thirteen patients with laboratory-reconfirmed M. ulcerans infection, nineteen clinically 
healthy household contacts and eighteen individuals from a neighboring BU non-endemic 
area were enrolled for this study (Table I and Table II). The frequency of immediate INF-
γ secreting cells in PBMC upon stimulation with IPP, IRIV and PPD was analyzed using 
an ex vivo ELISpot assay. Fig. 1 shows that the mean of SFU upon stimulation with PPD, 
IPP and IRIV was significantly lower (p=0.0086, p=0.001 and p=0.0002, respectively) in 
BU patients compared to non-exposed controls. In household contacts, the mean of SFU 
after IPP and IRIV stimulation was significantly higher compared to BU patients 
(p=0.005 and p=0.001, respectively)   while in PPD stimulated cultures no significant 
difference was observed (p=0.82).  
 
Recovery from systemic immuno-suppression after surgical treatment 
All patients enrolled for the study were treated by wide surgical excision of the BU 
lesions. Blood samples were collected several months after the first sampling (Table 2) 
and PBMC from both time points were analyzed in parallel using the same INF-γ 
ELISpot assay as above. A 3.9, 3.7 and 3.6 fold median increase in cellular responses 
against IPP, IRIV and PPD stimulation, respectively, was observed when PBMC taken at 
the two time points were compared (Fig. 2A). Statistical analysis confirmed this increase 
of responses as highly significant with p-values of 0.021 and 0.003, respectively, after 
IPP and IRIV stimulation. PHA stimulated control wells showed only a slight (1.7 fold) 
median increase between the two different time points analyzed (p=0.17) and in PPD 
stimulated cultures the boost was not significant (p=0.09). One representative example of 
an ELISpot analysis is shown in Fig. 2B with the numbers of SFU detectable after IPP, 
IRIV and PPD stimulation rising between 1st and 2nd sampling. In contrast, medium and 
PHA control wells remained at a comparable level between the two analyses. 
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IL-12 production in PPD stimulated PBMC is not affected in BU patients 
Next we wanted to determine whether the systemic suppression of INF-γ responses in BU 
patients is related to a diminished capacity to secrete IL-12. PBMC of nine patients and 
ten persons from BU non-endemic areas were stimulated with PHA or PPD and the total 
IL-12 concentration in cell culture supernatants was measured by ELISA (Fig. 3). 
Interestingly, the IL-12 concentrations in PPD stimulated PBMC of individuals living in 
M. ulcerans non-endemic regions were statistically lower compared to BU patients 
(p=0.011) while in PHA stimulated cultures no significant difference was observed 
(p=0.57) (Fig. 3). The mean IL-12 concentrations in supernatants of PPD and PHA 
stimulated cultures of PBMC obtained before or after surgical treatment showed no 
difference (Fig. 3).  
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Discussion 
An ex vivo ELISpot assay for detection of INF-γ secretion permitting the direct detection 
of individual antigen-specific T cells at low frequencies was employed in the current 
study [25]. The 48 h antigen challenge of PBMC suffices to engage cytokine production 
in the memory/effector T lymphocyte but not in naïve T cells and allows determination of 
frequencies and cytokine signatures of re-circulating antigen-specific T cells [25]. The 
frequencies of systemic INF-γ producing SFU after stimulation with IPP, IRIV or PPD 
was significantly reduced in BU patients compared to individuals living in a neighboring 
BU non-endemic area. This result is consistent with other reports demonstrating that 
PBMC from subjects with past or current M. ulcerans disease had reduced INF-γ 
production in response to PPD of M. tuberculosis and M. bovis or whole killed M. bovis 
BCG or M. ulcerans [14-18]. However, our data strongly indicate that reduced INF-γ 
production is not confined to immune responses specific for mycobacterial antigens or 
whole mycobacteria but extends to CD4 T cell responses specific for influenza virus [20] 
and Vγ2Vδ2 T cells [19].  
 
Reduced INF-γ production in BU patients could be the consequence of a genetic 
abnormality in T cell function predisposing for mycobacterial infections [11]. Therefore, 
we analyzed PBMC of BU patients sampled at two consecutive time points. When the 
paired PBMC samples were analyzed in parallel by ELISpot analysis, the numbers of 
INF-γ secreting cells after IPP, IRIV and PPD stimulation increased significantly after 
surgical treatment. Comparable numbers of SFU in PHA stimulated PBMC in paired 
samples excluded a general suppression of cellular immune responses in BU and 
variations in quality of PBMC sample cryo-preservation. To our knowledge, this is the 
first report demonstrating that antigen-specific INF-γ production in BU patients is 
coming back to normal levels after surgical treatment. Hence, confounding genetic 
defects do not seem to be responsible for the observed immuno-suppression. The 
question if INF-γ production in patients undergoing spontaneous healing of BU will also 
improve over time is not addressed here.  
IL-12 induces T and NK cells to produce several cytokines, including INF-γ [26]. Total 
IL-12 concentrations in culture supernatants of PPD stimulated PBMC were statistically 
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higher in BU patients (treated and untreated) than in the controls. This may reflect a 
compensatory mechanism of the immune system to restore INF-γ production and 
indicates that the observed reduction in systemic INF-γ responses is not caused by 
diminished IL-12 production. Different cytokine expression profiles in both PBMC and 
skin lesions were described in patients suffering from the nodular and ulcerative forms of 
BU. Nodules were associated with higher INF-γ and lower IL-10 production and BU with 
lower INF-γ and higher IL-10 production [17]. Within the limited number of BU patients 
enrolled in our study, a relationship between different stages of BU disease and reduction 
of INF-γ secretion was not observed.  
 
Vγ2Vδ2 T cells compose the majority of human γδ T cells in circulation and among their 
defined ligands is IPP, a metabolite found in prokaryotic and eukaryotic cells including 
mycobacteria [27]. Studies in rhesus monkeys provided evidence that Vγ2Vδ2 T cells 
contribute to adaptive immune responses in mycobacterial infections [28]. A correlation 
between the absence or loss of Vγ2Vδ2 T cells and the extent of M. tuberculosis disease 
has been described [29]. An impaired ability of Vγ2Vδ2 T cells to produce cytokines or 
proliferate in response to phosphorylated microbial metabolites was observed in active M. 
tuberculosis pulmonary disease [30-32]. Interestingly, in 10 out of 13 BU patients 
analyzed here, the ex vivo INF-γ secretion of IPP-reactive Vγ2Vδ2 T cells increased 
significantly after surgical treatment.  
 
The diffusible macrolide toxins produced by M. ulcerans are considered as virulence 
factors responsible for pathogenicity of M. ulcerans and it has been hypothesized that 
lack of inflammatory responses in BU lesions are related to local immuno-suppressive 
activities of the mycolactones [6;33;34]. The treatment-associated reversal of immune 
suppression may indicate that mycolactones exert apart from local also systemic effects. 
Alternatively, additional other immune-suppressive mechanisms may be operative in 
chronic M. ulcerans disease. PBMC from healthy contacts of TB patients and TB patients 
with limited disease produce large quantities of  INF-γ in response to whole 
mycobacteria, PPD of M. tuberculosis, ESAT-6, 16-kDa and 38 kDa proteins [35-39]. In 
contrast, PBMC of active TB patients with advanced disease produce low quantities of 
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INF-γ after similar stimulation and following effective drug treatment the INF-γ secretion 
improved [39;40]. Possible candidate structures mediating immune suppression in M. 
tuberculosis isolates like phenolic glycolipids have been described [41;42]. In leprosy 
induction of regulatory or suppressor T cells mediating immune suppression in affected 
hosts has been proposed [43;44]. Our findings, within their limits due to the small 
number of BU patients analyzed and the timing of the blood samples drawn, may indicate 
that mycolactone-independent immunosuppressive mechanisms common to chronic 
mycobacterial infections contribute to the reduction of systemic INF-γ responses in BU 
patients.  
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Characteristic 
 
Buruli ulcer 
patient 
(n = 13) 
 
Household 
contacts 
(n =19) 
 
Controls from non-
endemic area 
(n = 18) 
Sex     
     Male 5 (39%)  6 (32%) 8 (44%) 
     Female 8 (61%) 13 (68%) 10 (56%) 
Median age (years) 15 15 29.5 
Age range (years) 6 - 45 6 - 56 24 - 65 
BCG scar present (%) a 69 52 55 
 
Table I: Characteristics of BU patients, household contacts and controls from a BU non-
endemic area enrolled in the study. 
a  % values calculated for 13 patients, 14 household contacts and 14 controls, respectively. 
Five household contacts and four non-exposed controls remained with uncertain scar 
status. 
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patient 
 
age 
 
gender 
 
clinical 
forma 
 
BCG 
statusb 
 
AFBc 
 
cultured 
 
PCRe 
 
1st blood 
sample f 
 
2nd blood 
sample f 
P03 45 f ulcerative - + + + 3 mo 11 mo 
P04 9 f plaque + - + + 0 8 mo 
P05 10 m nodule + + + + 0 8 mo 
P08 16 m ulcerative - + + + 4 mo 14 mo 
P09 5 f ulcerative + + - + 3 mo 12 mo 
P11 20 f ulcerative + + + + 7 d 7 mo 
P12 16 m ulcerative + - - + 3 mo 12 mo 
P13 11 f ulcerative - + + + 7 d 7 mo 
P14 15 m plaque - - - + 7 d 8 mo 
P15 7 f ulcerative + + + + 0 9 mo 
P19 6 m nodule + + + + 0 6 mo 
P21 17 f nodule + + - + 0 5 mo 
P22 17 f nodule + + + - 0 5 mo 
Table II:  
Clinical data of patients presenting with lesions due to confirmed M. ulcerans infection 
a clinical forms of BU disease were graded according to the WHO case definition [1]. 
b
 BCG status was determined by confirmation of the presence of a BCG scar by two 
persons. 
c
 Acid fast bacilli detection was performed by direct smearing of tissue exudates followed 
by Ziehl-Neelsen staining [1]. 
d
 Culture of M. ulcerans according to [22]. 
e
 IS2404 PCR analysis according to [23]. 
f
 Time of blood sample collection. Time 0 is time of surgical treatment. 
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Fig. 1.  
Quantification of ex vivo INF-γ secreting cells by ELISpot analysis after stimulation of 
PBMC with IPP (◊), IRIV (○) and PPD (∆).  
 
PBMC derived from BU patients (BU), household contacts (HC) and controls from a BU 
non-endemic area (NC) were thawed into cell culture medium and kept overnight in the 
presence or absence of the different stimuli. For the detection of IFN-γ producing cells , 2 
×105 PBMC/well were plated in triplicate wells and spots were developed after 24 h. 
Delta SFU = mean of SFU of stimulated triplicate cultures – mean SFU of un-stimulated 
triplicate cultures. Data from each individual analyzed are shown separately. Mean 
SFU/106 PBMC were 26 (6 – 102), 137 (57 – 327) and 262 (157 – 436) after stimulation 
with IPP in BU patients, HC and NC, respectively. In IRIV-stimulated cells, the mean 
SFU/106 cells were 22 (7 – 70), 135 (83 – 221), 149 (56 – 394) in BU patients, HC and 
NC, respectively. After PPD stimulation, 88 (35 – 223), 39 (14 – 106) and 212 (100 – 
445) SFU/106 PBMC were recorded in BU patients, HC and NC, respectively. The values 
given in brackets are the 95 % confidence intervals of the geometric means of SFU. Data 
of patients P03, P08, P09 and P12 are shaded in grey. 
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Fig. 2A.  
Frequency increase of antigen-specific ex vivo INF-γ secreting cells in BU patients.  
 
PBMC of thirteen BU patients sampled  at two time points (Table II) were thawed into 
cell culture medium and kept overnight in the presence or absence of IPP (◊), IRIV (□), 
PPD (∆) and PHA (○). For the detection of INF-γ producing cells , 2 ×105 PBMC/well 
were plated in triplicate wells and spots were developed after 24 h. Delta SFU were 
calculated as described in Fig. 1. Given is the ratio of SFU obtained after 2nd sampling / 
1st sampling. Data of patients P03, P08, P09 and P12 are shaded in grey. 
0.1 
1 
10 
100 
1000 
de
lta
 
SF
U
/1
06
 
PB
M
C
 
(2n
d  
sa
m
pl
in
g) 
/  
de
lta
 
SF
U
 
SF
U
/1
06
 
PB
M
C
 
(1s
t  
sa
m
pl
in
g) 
PHA PPD IRIV IPP 
CHAPTER 7. Systemic suppression of IFN-γ responses 
 112 
 
 
 
 
 
 
 
Fig. 2B.  
Representative INF-γ ELISpot patterns of BU patient P21.  
PBMCs of BU patient P21 were obtained immediately before surgical excision of the BU 
lesion (1st sampling) and 5 months later (2nd sampling). Parallel analysis of both samples 
was conducted in triplicates arranged horizontally with 2 x 105 cells/well plated. The 
different stimulators used are given on the right and the numbers of SFU/well are shown 
on the lower left corner.   
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Fig. 3. 
 
Total IL-12 concentrations in cell culture supernatants of PHA and PPD stimulated 
PBMC of nine BU patients obtained at the two different sampling time points (Table II). 
Mean of total IL-12 concentration (given in pg/ml) in PPD stimulated cultures was 543 
and 750 after 1st and 2nd sampling, respectively, and in PHA stimulated cultures 348 and 
472, respectively. PBMC of ten individuals living in a neighbouring M. ulcerans non-
endemic region were treated similarly and the mean total IL-12 concentrations after PPD 
and PHA stimulation were 276 and 402, respectively.  
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Abstract  
 
The serum concentration of INF-γ, TNF-α, IL-4 and IL-6 was assessed in Buruli ulcer 
patients (BU), household contacts (HC) and non-exposed controls (NC). Our results 
demonstrate that about 75 % of BU and HC have enhanced INF-γ and TNF-α serum 
levels compared to NC indicative for immune activation by M. ulcerans exposure. 
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Buruli ulcer (BU), is a chronic skin disease caused by Mycobacterium ulcerans (8). 
Clinical presentations of BU are variable, but usually the disease starts as painless 
nodules or papules in the skin and if left untreated gradually causes massive skin 
ulcerations (5). M. ulcerans infection occurs commonly in areas related to rivers, swampy 
terrain or lacustrine systems and is particularly prevalent among poor populations in 
remote rural areas in West Africa where modern medical amenities are lacking (1). The 
mode of transmission of BU remains elusive and it has been suggested that trauma to the 
skin by a contaminated environment (e.g., soil, water, vegetation, insect vector) 
constitutes one possibility of spread (11). Alternatively, M. ulcerans could be inhaled or 
ingested and then reactivated in low temperature areas of the body at the sites of trauma 
(6). Without a serological or cellular diagnostic test system at hand for M. ulcerans 
exposure of humans it is unclear which proportions of people living in an BU endemic 
focus are actually exposed to M. ulcerans and who is prone to progress to clinical 
disease.  
Cytokines regulate cellular immune interactions and are produced by a broad range of 
cells including lymphocytes, monocytes, macrophages, fibroblasts, neutrophils, 
endothelial cells or mast cells (2). The presence and concentration of human cytokines 
can be assessed conveniently in serum or plasma samples using commercially available 
enzyme immunoassays. Although serum cytokine levels do not necessarily reflect the 
peripheral blood mononuclear cellular cytokine production they can serve as indicator of 
the activation of cellular immune system (7). In this study we examined the serum 
cytokine levels in Buruli ulcer patients (BU) and compared it to contacts of these patients 
(HC) and individuals residing in neighbouring BU-non-endemic areas (NC). The aim was 
to establish whether sharing the environment with BU results in immune activation 
events easily assessable in serum or plasma samples.  
 
This study was approved by the Institutional Review Board of the Noguchi Memorial 
Institute for Medical Research. 35 BU, 18 HC and 10 NC were involved and informed 
consent was obtained from all the subjects and or their parents. (Table 1). BU were 
confirmed microbiologically by culture, polymerase chain reaction and Ziehl-Neelsen 
staining (16). All patients were treated according to the guidelines of the national BU 
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control program by surgical excision. The first blood samples were collected from all BU 
before treatment and from seven BU second and third blood samples were collected one 
and two months after surgical treatment, respectively. Sera were collected after 
centrifugation and stored at -70° C until analysis. The serum samples were analyzed for 
IL-4, IL-6, IFN-γ and TNF-α concentration by using pairs of cytokine-specific 
monoclonal antibodies according to the manufacturers' instructions (Mabtech, Sweden 
for IL-14, IL-6 and TNF-α and Endogen for IFN-γ). Each plate included a cytokine 
standard of recombinant human cytokine and negative controls. All specimens were 
measured in duplicate and the means of the two values were used in all analyses. 
Detection limits were 1 pg/ml for IL-4, 8 pg/ml for TNF-α, 8 pg/ml for IFN-γ and 
7 pg/ml for IL-6. Data were analyzed using the STATA program (Stata Corporation). 
Comparisons among the paired samples of the BU patients were performed using the 
Wilcoxon signed-rank test, while the Wilcoxon rank-sum test was used to analyze the 
significance of differences among BU, HC and NC. Data were considered statistically 
significant when P < 0.05. 
The mean INF-γ serum level in BU, HC and NC was 34.6, 24.7 and 0 pg/ml, 
respectively, which was significantly higher in BU and HC compared with NC (p = 
0.0002 and p = 0.0003), respectively (Figure 1A). There was no significant difference 
between serum INF-γ levels in BU patients with pre-ulcerative and ulcerative stages 
(Figure 1B).  
The mean TNF-α concentration in BU, HC and NC was 823.6, 613.3 and 325.3 pg/ml, 
respectively. The TNF-α levels differed significantly between BU and NC (p = 0.01) and 
HC and NC (p = 0.02) (Figure 1A). BU patients with ulcers had significantly lower levels 
of TNF-α (mean = 586 pg/ml) compared to patients with pre-ulcerative stages (mean = 
1341.9 pg/ml) (p = 0.006) (Figure 1B).   
The mean IL-6 serum concentrations in BU, HC and NC were 38.7, 51.5 and 4.5 pg/ml, 
respectively. The IL-6 values between BU and NC but not HC and NC differed 
significantly (p = 0.04) (Figure 1A). In BU, HC and NC, the mean IL-4 levels assessed 
were 306.9, 291.8 and 132.4 pg/ml, respectively and no significant differences between 
the groups analyzed was detectable (Figure 1A). For all cytokines assessed, no significant 
changes were observed before and after surgical treatment within a follow up period of 
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60 days (Figure 1C). In summary, 26 out of the 35 BU (74 %) and 14 out of the 18 HC 
(78 %) had detectable levels of IFN-γ in their serum. 28 BU (80 %) and 15 HC (83 %) 
had TNF-α levels higher than 325 pg/ml representing the mean TNF-α level detected in 
NC. 24 BU (68 %) and 13 HC (72 %) had both enhanced concentrations of IFN-γ and 
TNF-α compared to NC. 15 BU (45 %) and 4 HC (22 %) showed  IL-6 levels above the 
mean of the NC.  
  
In the present study statistically significant differences in the INF-γ and TNF-α serum 
concentrations between BU and NC and interestingly between HC and NC were found. 
Diaz et al., have shown that antibodies specific for an 18 kd heat shock protein of M. 
ulcerans were frequently found in serum of BU and HC, but rarely in African NC. The 
authors concluded that a considerable fraction of HC is exposed to M. ulcerans antigens 
resulting in specific humoral immune responses {unpublished}. These data prompted us 
to analyse serum cytokine levels as an indirect measure of immune activation and to shed 
more light on the potential involvement of distinct cytokines in BU. The approach 
certainly has limitations since serum cytokine levels can be affected by receptor binding, 
temperature degradation, urinary excretion and cytokine breakdown within receptor 
bearing cells.  
INF-γ plays a fundamental role in cellular immune responses directed against 
mycobacteria since patients with defective receptors for INF-γ are highly susceptible to 
severe mycobacterial diseases (10). Similar to our results, serum INF-γ levels in active M. 
tuberculosis patients were higher compared to healthy controls with positive tuberculin 
skin tests (13, 14). A number of studies have shown that INF-γ production of PBMC after 
antigen-stimulation were reduced in BU compared to NC (3, 4, 12, 15, 16). The 
discordance between enhanced serum INF-γ levels and INF- γ secretion by PBMC of BU 
suggests that INF- γ might not be mainly derived from PBMC but rather derived from 
tissue leakage into circulation. Serum IFN-γ levels in BU before and up to 2 months after 
surgical treatment did not change significantly in contrast to antigen-stimulated PBMC 
(16).  
Side effects of anti-TNF-α therapies have demonstrated that it is crucial for immune 
control of mycobacterial infections in humans (9). Interestingly, the TNF-α level was 
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significantly higher in pre-ulcerative lesions of BU (i.e. more localised lesions) compared 
to later, ulcerative lesions supporting the involvement of this cytokine in immune 
responses against M. ulcerans. Similar to tuberculosis, the serum concentration of IL-6 
was significantly higher in BU compared to NC (14) and was highest in pre-ulcerative 
lesions. Hence, IL-6 might be involved in the immune responses against active M. 
ulcerans infections, particularly during early stages of the disease. In summary, we 
provided first evidence that about 75 % of HC showed enhanced levels of INF-γ and 
TNF-α indicative for immune activation. Possibly, exposure to M. ulcerans contributes to 
this immune activation supporting the hypothesis that so far unknown factors contribute 
to development of clinical disease in BU. In future it would be interesting to monitor 
persons with elevated levels of INF-γ and TNF-α regularly for eventual development of 
or protection from BU.  
 
This study was supported in part by the Stanley Thomas Johnson Foundation and the 
Ghana Government.  
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 BU (Pre-ulcer) BU (ulcer) HC NC 
 (n = 11) (n = 24) (n = 18) (n = 10) 
Age 18 (4-54) 13.2 (3-45) 15.6 a (6 – 40) 29.2 (9.5 – 58) 
Gender 
female 6 
male 5 
female 16 
male 8 
female 8 
male 10 
female 5  
male 5 
 Cytokine levels assessed  
IFN-γ 45.3 b (0-285.6) 29.7 (0-142.2) 24.7 (0-106) 0  
IL-4 427.2 (0-1403) 251.7 (0-1262) 291.8 (0-1115) 132.4 (0-400) 
IL-6 59.8 (0-159.4) 29 (0-257) 51.5 (0-372) 4.5 (0-45) 
TNF-α 1341.9 (0-3758) 586.0 (0-1610) 613.3 (0-1235) 325.3 (0-957) 
 
 
Table I:  
Overview of persons enrolled in the current study and serum cytokine levels measured by 
ELISA.  
 
a  
mean age of group, range is given in brackets 
b  calculated arithmetic mean of individual measurements, ranges are given in brackets 
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Figure 1A: Circulating IFN- γ, IL-6, IL-4, and TNF-α level in BU, HC and NC. The dots 
represent individual measurements and the horizontal is the mean value for the different 
groups. 
 
Chapter 8. Serum levels of interferon gamma and tumor necrosis factor alpha 
 127 
 
nodule ulcer
0
100
200
300
pg
/m
l I
N
F-
γγ γγ
nodule ulcer
0
1000
2000
3000
4000
pg
/m
l T
N
F-
a
nodule ulcer
0
500
1000
1500
pg
/m
l I
L-
4
nodule ulcer
0
100
200
300
pg
/m
l I
L-
6
 
 
 
Figure 1B:  Comparison of serum levels of IFN-γ, IL-6, IL-4, and TNF-α in BU with pre-
ulcerative lesions and ulcerative lesions. The black dots represent individual 
measurements and the horizontal line is the groups mean values. 
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Figure 1C: Serum samples were collected from BU before surgery, 30 and 60 days after 
surgical treatment. Cytokine levels were analysed by ELISA and expressed in pg/ml. 
Each individual analyzed is depicted individually by a distinct symbol. 
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9.1 General discussion  
Even though Buruli ulcer (BU) was discovered in the 19th century it was largely 
neglected until a century later, in 1997, that the World Health Organisation (WHO) 
recognised it as a disease that creates a considerable public health burden, particularly in 
West-Africa. At a meeting in Yamoussoukro in 1998 the WHO and the countries affected 
declared the need to fight this disease. It was realised that to be able to control BU, there 
is the need to improve the scarce understanding of the various characteristics of the 
disease. This led to the formation of the BU technical advisory group (1). The 57th WHO 
Assembly in 2004 not only reiterated the importance of BU but pinpointed a number of 
areas where research should be intensified: 1) development of simplified diagnostic tools, 
2) development of new drugs to improve therapy, 3) host immune response, and 4) 
development of tools to understand the transmission of the disease in order to enhance 
control and prevention of the disease.  
The present PhD work contributed in the areas of laboratory confirmation of clinical 
diagnosis and cultivation of M. ulcerans from clinical samples, the significance of 
antibiotics in the treatment of BU, the usefulness of molecular methods in studying 
transmission and the understanding of immune response in M. ulcerans infection. 
 
9.1.1 Cultivation of M. ulcerans and laboratory confirmation of clinical diagnosis  
In endemic countries of Africa, cases of BU are diagnosed mainly on clinical grounds, 
due to limited access to laboratory facilities (2). The presentation of typical indolent, 
painless, undermined edges and necrotic slough lesion allows a straightforward diagnosis 
of ulcerative lesions. It is more difficult, however, for the nodule, plaque and oedema 
forms and even more so for atypical forms, which can be confused with other skin 
diseases (3). Thus reconfirmation of clinical diagnosis of cases is very important to 
prevent unnecessary surgical excision and/or antimycobacterial drug treatment of patients 
with non-BU lesions and for epidemiological surveillance. The available tests for 
confirmation of cases include: 1) direct smear examination with Ziehl-Neelsen staining to 
detect the presence of acid-fast bacilli in patholological sample 2) cultivation of M. 
ulcerans on solid medium at 32°C 3) detection of M. ulcerans DNA by PCR and 4) 
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histopathology (3). Of all the above methods the most definite confirmatory is the 
isolation of M. ulcerans by culture from samples obtained from lesions. However, this 
method is expensive and difficult and the recovery rate can be as low as 20% (4).  
 
In previously reported studies, clinical specimen were collected in remote endemic areas 
of Africa and shipped to research or diagnostic laboratories in Europe or North America 
(5,6). A major contribution of the present PhD work was the establishment of a very 
successful culturing system in an endemic country (Ghana). It was demonstrated that a 
recovery rate of more than 70% can be achieved within the framework of an efficient 
partnership between a health delivery institution and a bio-medical institute in an 
endemic country (chapter 3). The success in primary isolation of M. ulcerans depended 
on the emphasis both partners put on the optimisation of sampling procedures and 
specimen handling prior to cultivation. We showed that aseptic transfer of the biopsy 
specimen directly into a special transport medium containing antibiotics, maintenance of 
the cold chain between health facility and the laboratory, and cultivation within 48 hours 
of sample collection were critical to obtain an adequate yield of M. ulcerans. 
 
 In addition to the sampling process, the removal of contaminating fast growing bacteria 
by a decontaminating agent before culture was very important. There are two interrelated 
factors involved in the recovery of M. ulcerans from clinical specimens. One is the ability 
of the decontaminating agent to destroy non acid-fast contaminants, whose presence 
could cover the detection of M. ulcerans growth. The other factor is the decontaminating 
agent’s direct effect on the viability of M. ulcerans (7). In a culture optimisation study we 
demonstrated that oxalic acid decontamination (8) was the best for the recovery of viable 
M. ulcerans from clinical samples and is also the best in the removal of contaminating 
organisms.  
 
Finally, the medium for cultivating bacteria is important. Mycobacteria differ in their 
preference for carbon source utilisation, with variation across the genus. This is 
particularly true with regard to glycerol utilisation. Under laboratory conditions glycerol 
is the preferred carbon source for a number of mycobacterial species, including M. 
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tuberculosis.  However, M. bovis, M. africanum and M. microti are all unable to use 
glycerol as a sole carbon source, and pyruvate is therefore routinely added to glycerinated 
media to enable growth (9). The preferred carbon source for M. ulcerans had not been 
established. Our study showed for the first time that M. ulcerans prefers glycerol to 
pyruvate as source of carbon and so a medium for M. ulcerans should contain glycerol.     
 
Even under optimal conditions, culture is a time consuming process and only yields 
results after several weeks of cultivation. Because of this, and the low recovery rate 
generally reported, more efforts are being put in the improvement of PCR procedures for 
detection of M. ulcerans DNA in clinical specimen. Most research groups now use the 
high copy number insertion sequence, IS2404 in the detection of M. ulcerans. Therefore 
we later included IS2404 specific PCR and direct acid-fast bacilli staining in a laboratory 
diagnosis system. The combined methods were used in a large series of patients to assess 
clinical diagnosis of BU cases seen at the Amasaman Health Centre. This helped the 
clinician in her case definition and also validated clinical diagnosis (chapter 4). This is 
essential as sensitivity of clinical diagnosis in experienced hands was only about 50% in 
one study (10).  To the best of our knowledge, this is the first study that involved a large 
case series assessing the accuracy of clinical diagnosis.  
 
The WHO recommends that case reconfirmation should be done on the basis of positive 
results for two diagnostic tests (3). In our study, more than 90% of the clinically defined 
cases were confirmed in the laboratory. Based on this result, we suggest that in an 
endemic country like Ghana, where clinical features of BU are well known to clinicians, 
one positive test is regarded sufficient in combination with clinical diagnosis carried out 
by a clinician who has extensive experience with BU diagnosis. In addition to individual 
case confirmation, we formally confirmed that the Ga district is endemic for BU as more 
than 90% of the lesions presented at the Amasaman Health Centre were confirmed 
microbiologically as BU.   
 
Our findings indicate that there is a need for education of the rural population, as more 
than 50% of the cases were reported late. Such an education should stress the need for 
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early detection of nodular lesions, which can reduce the length of stay in hospitals and the 
need for reconstructive plastic surgery. Also the education should make the rural people 
know that BU is the result of an infection and not caused by witchcraft.  
 
In spite of the successful establishment of an efficient cultivation system in Ghana, it is 
not feasible to provide this service nationwide and simple diagnostic assays that are rapid, 
inexpensive, and do not require highly trained personnel or a complex technological 
infrastructure are required, for differential diagnosis of very early nodular cases to limi 
since with the introduction of 8 weeks of drug treatment before surgery (11), it is 
necessary to conduct pre-surgery confirmation to avoid unnecessary drug treatment as a 
result of false clinical diagnosis. A very attractive option will be immunodiagnostic 
procedures, which will not require the use of an invasive procedure for sample collection, 
as the collection of even needle biopsies may enhance the spread of the pathogen. In a 
report of a case-control study conducted in Ghana, the authors achieved a specificity of 
serological testing; 85% BU patients were IgM positive to M. ulcerans culture filtrate, 
4.5% healthy contacts were positive and none of the TB control patients were positive 
(12). This promising result may need to be investigated further by identifying specific 
immunodominant antigens and testing in a larger patient population with appropriate 
controls. In addition, the possibility of using serodiagnosis for assessing exposure has 
been evaluated in a pilot study using an immunodominant 18kDa protein (13) and this 
can be used to identify newly infected people and provide them with preventive therapy, 
as is being done in the case of tuberculosis for risk individuals (14).  
 
In addition to culture being the most definite method for microbiological confirmation of 
clinical diagnosis, it also allows the raising of a collection of isolates that is helpful in the 
understanding of the epidemiology of the microbe being studied. This is very crucial in 
the case of M. ulcerans for which current knowledge is very scanty. Some of the 
questions that need to be addressed using strain collections are the mode of transmission, 
strain variability with regard to virulence phenotypes and searching for efficacious drugs 
for chemotherapy. Within the frame-work of this thesis, we were able to raise a large 
collection of M. ulcerans isolates not only from the Ga district but also from other 
CHAPTER 9. General discussion and conclusion 
 136 
endemic districts in Ghana (chapters 3 & 4). These isolates were later used in the analysis 
of variability in drug sensitivity and for the identification of variable genetic markers 
within the clonal population of African M. ulcerans isolates (chapters 5& 6).  
 
9.1.2 Antibiotic Treatment  
Prior to 2004 the general impression was that antibiotic therapy is of no benefit in BU 
treatment and therefore the recommended standard treatment was wide surgical excision 
followed by skin grafting. Many antimycobacterial drugs were effective in vitro but their 
efficacy was not reflected in vivo, at least in humans (15,16). This inconsistency has been 
explained as being due to the inability of drugs to penetrate tissues and/or to the 
persistent action of the toxins secreted by the bacillus. In mouse model studies, however a 
combination of rifampicin and aminoglycosides showed inhibitory activity (17,18). This 
led to a series of further studies in Ghana (19), Benin (20) and the Ivory-Coast (21). A 
randomized, placebo-controlled pilot study conducted in Ivory-Coast tested the efficacy 
of a combination of dapsone and rifampicin, in the management of BU. Their findings 
indicated a marginal benefit with antibiotic treatment; however the groups were 
dissimilar at the start of the study.  In Ghana, a small clinical trial revealed that a course 
of at least four weeks of rifampicin and streptomycin inhibits the growth of M. ulcerans 
in pre-ulcerative lesions. In an observational study conducted in Benin all the 99 patients 
who received a combination of rifampicin and streptomycin were healed after 8 weeks 
treatment (22).  
 
Based on the results of these studies, the WHO now recommends 8 weeks treatment with 
a combination of rifampicin and streptomycin before surgery. With this treatment, 
experts hope to reduce the indications for surgery or the extent of surgery, and also the 
relapse rates (23). A number of arguments have been put forward against this 
recommended combinatory treatment (24).  The first argument was that there were flaws 
in the study designs; for example the sample size for the randomised control trial at 
Agroyesum in Ghana was small and also the study design did not analyse the efficacy in 
preventing relapse or disseminated infection.  Another draw back was, none of the drug 
trial studies isolated M. ulcerans from the patients for in-vitro susceptibility studies. A 
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second argument is that the use of the combinational therapy for short time without 
proper microbiological investigation could increase the risk of developing resistant 
tuberculosis because rates of TB co-infection with BU have not been looked at in-depth 
in any of the endemic countries. The risk that BU patients are co-infected with TB in the 
BU endemic regions of Africa is very high, as all the worst affected countries are 
endemic for tuberculosis and the above antibiotics are very essential for their TB control 
programs. Consequently, the judicious use of these antibiotics is very essential to prevent 
an increase in resistant strains of tuberculosis.  It is known that in developing countries 
individuals with TB and other mycobacterial infection at certain time point carry high 
bacterial loads which predisposes the selection of resistant cases (25). If the rate of BU 
continues and hence the use of this therapy increases the problem will become serious.  
  
Although there are no reports in literature indicating clinical M. ulcerans isolate resistant 
to rifampicin, there have been previous observations of the ineffectiveness of these drugs 
in treating BU (26,27). In a mouse model study, Bentoucha et al (28) showed that non-
judicious use of rifampicin, as in monotherapy, can cause the rpo B gene to mutate, 
leading to conversion of sensitive strains to resistant ones. There is the danger that M. 
ulcerans will also develop resistant to these drugs. It is therefore imperative to conduct 
periodic surveys to monitor the susceptibility pattern of MU to these drugs. The 
inexpensive conventional proportion method in use at present is technically demanding 
and very slow, requiring at least 8 weeks to complete an experiment (16), while the more 
rapid BACTEC method requires the use and disposal of radioactive material which is 
beyond the means of poor endemic countries (29). Within the framework of this PhD a 
simpler and technically not demanding procedure, Microplate Alamar Blue Assay 
(MABA) (30,31) was adapted to test the sensitivity of M. ulcerans to antibiotics.  The 
adopted MABA, which is a more rapid, easier and cheaper procedure with high 
throughput, will make it easier to conduct susceptibility assays, which can be used in the 
screening of new compounds as well as of drugs currently in-use.  In developed 
countries, this assay is usually read with a spectrophotometer (30,31). In our study the 
end result was read visually and the agreement with the gold standard proportion method 
was high; more than 90% (chapter 6). 
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The MABA method we established allowed us to determine the susceptibility pattern of 
M. ulcerans isolates from Ghana and identified both rifampicin and streptomycin 
resistant strains among our strain collection. This result was reconfirmed using the 
proportion method (chapter 6). These findings raise major concern and more extensive 
studies are required to clarify whether resistance to rifampicin and streptomycin is 
commonly found in African M. ulcerans strains. In addition analysis of strains from 
patients not responding to rifampicin and streptomycin is very important for planning of 
an alternate regimen for re-treatment.  
From the above discussions, it is clear that the development of an effective drug for oral 
treatment suitable also for the treatment of small children is a research priority in the 
control of BU. The MABA procedure can be used to screen new compounds to determine 
in vitro activity against M. ulcerans for onward in-vivo studies. These screenings should 
take into consideration not only susceptibility to M. ulcerans but M tuberculosis as well. 
 
9.1.3 Genetic fingerprinting and transmission 
The mode of transmission of BU is still an enigma. Endemic foci are normally close to 
areas with slow flowing or stagnant waters, often caused by human environmental 
disturbance activities. In Uganda, increased numbers of BU cases occurred among 
refugees when they were living close to the Nile River, but the numbers dropped when 
the refuges were moved to a different location (32). Also the first documented cases of 
BU were described among persons living in a swampy area in Bainsdale in Australia 
(33).   In the current work we were able to confirm this with microbiologically-confirmed 
BU, as more than 90% of all the cases were from both Amasaman and the surrounding 
villages, or from towns close to the Densu River in the Akwapim south district (chapter 3 
& 4). Both Amasaman and its surrounding villages are all dotted with a number of 
stagnant pools which are the result of major sand winning activities for construction in 
the near-by cities of Accra and Tema. The Densu River is dammed for the provision of 
potable water for the above cities and has led to increase in vegetation and flows very 
slowly along these villages.    
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An important aspect in the control of infectious disease is the identification of risk factors 
that increase the chance that the host will come into contact with the pathogen. 
Understanding of risk factors makes it possible to identify preventable risks and to 
implement effective public health measures. Genetic fingerprinting of pathogenic bacteria 
has been extremely useful for monitoring patterns of transmission in human populations. 
It has helped in tracking the transmission links between individuals, and also 
demonstrating instances in which related people were infected with unrelated strains. 
With the inception of active DNA fingerprinting of M. tuberculosis isolates, a number of 
open epidemiological questions with regard to TB control have been answered. An active 
DNA fingerprinting of M. tuberculosis in New-York city identified risk factors (e. g. HIV 
infection, living in crowded homes) that enhance the risk of acquiring recent tuberculosis 
and activation of latent infection. High risk individuals who are latently infected are 
given prophylaxis (14,34-36).  
 
M. ulcerans is said to have a ‘very limited polymorphic’ genome so standard molecular 
typing methods have turned out not to be able to discriminate strains of M. ulcerans from 
a specific area. Especially none of the published studies has identified genetic 
heterogeneity in African isolates (37-39). Within the frame work of this PhD, we applied 
Variable Number of Tandemly Repeated (VNTR) sequence typing to the large collection 
of isolates raised from five different districts in Ghana and found for the first time genetic 
polymorphism in isolates from an African country. More importantly, there were 
variations in distribution of the different genotypes between the two main endemic areas; 
while genotype 3 strains were found only in the Ga district, genotype 2 strains were 
identified only in the Amansie West district. The common allelic combination found in 
other African isolates (genotype 1) was rarely found in Ghana. Two of the three 
genotypes which were found in recent Ghanaian isolates were not found in other 
countries. This showed the emergence and spreading of new variants within Ghana 
(chapter 5).  
 
Further investigation of the temporal and spatial patterns of emergence and spreading of 
genotypes may contribute in future to our understanding of the transmission and 
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epidemiology of Buruli ulcer. This study also confirmed the discriminating power of 
VNTR-based typing for genotyping of M. ulcerans isolates. However, the resolution 
obtained by the VNTR typing is not enough for more detailed micro-epidemiological 
studies. Future studies should search for more polymorphic VNTR loci. The possibility of 
this will be enhanced by the availability of the genome sequence. Future micro-
epidemiological studies based on highly discriminating genetic fingerprinting method 
could answer a number of questions such as: whether most of the recurrences are caused 
by exogenous re-infection, incomplete surgery or haematogenous spread to other sites; 
whether in patients with multiple lesions, all lesions are caused by the same strain or by 
multiple infections; whether person to person transmission is rare or frequent. 
In addition we found one dominant strain which seems to be more successful over the 
rest and phenotypic characterisation will help to understand the basis of some virulence 
of M. ulcerans.   
 
Three major hypotheses exist for the acquisition of M. ulcerans infection (40). The first 
hypothesis is that M. ulcerans infection is acquired by contact with a contaminated 
environment, as reservoirs including biofilm on vegetation in water (41). The 
environmental bacteria may gain access through wounds or minor abrasions of the skin 
and sub-cutaneous inoculation may result in multiplication of the pathogen in the sub-
cutaneous fat (42). Supporting this hypothesis, Stinear et al used a magnetic bead 
sequence capture-PCR to detect two M. ulcerans sequences in water and plant material 
samples collected from two endemic foci. Both were positive for M. ulcerans  but, nearby 
sites and sites unrelated to the endemic areas were negative (43).  Case control studies 
conducted in endemic foci have identified either swimming or fishing as a risk for 
acquiring infection (44). Distribution of lesions over body surface area in a case series 
study carried out in Ghana indicated that infection was acquired by activities near the 
ground such as farming or playing (45).  The second hypothesis suggests that infection is 
acquired by aerosol spray of contaminated water. This is backed by the observation of an 
outbreak of M. ulcerans in area near a golf course irrigation system in Australia (46).  
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A third hypothesis is that infection may be through intermediate hosts.  The third 
hypothesis is supported by a number of studies: using PCR, M. ulcerans has been 
detected in biting insects (47), mosquitoes from Australia and the salivary glands of the 
carnivorous insect, Naucoris spp. For most of the environmental studies, the IS2404 PCR 
which was used as the detection marker is now known not to be absolutely specific for M. 
ulcerans as other environmental mycobacteria have been found to contain this insertion 
sequence (48,49). Hence the final proof method is the isolation of M. ulcerans from these 
supposed intermediates. In the vast majority of cases it was not possible to culture M. 
ulcerans from the supposed intermediates, as most of the samples were heavily 
contaminated and had been transported for long distances out of the endemic countries 
before culturing. Only two pure cultures have been identified from environmental sources 
(50). The inability to cultivate this organism from environmental sources may be due to 
inadequate sampling, conditions of transport, decontamination and culture conditions.  
The establishment of the improved cultivation method in Ghana will now enhance 
cultivation of M. ulcerans from the supposed hosts.  
 
In addition to elucidating transmission among human populations, genetic fingerprinting 
could also be useful in providing evidence based data to confirm or disprove the 
hypothesis that an intermediary host is involved by identifying animal reservoirs. The 
principle behind this is similar to what is used in tracking the source of infections in 
human populations. That is by comparing the relatedness of genetic fingerprints between 
human clinical isolates and that of isolates obtained from suspected animal intermediary 
host/s. Such phylogenetic analysis can help in identifying the pattern/sequence of 
transmission.  Marsollier et al carried out genetic fingerprinting on isolates obtained from 
plants, aquatic insects and clinical isolates from the same region in Ivory-Coast. Findings 
from this study showed that plant-associated M. ulcerans had the same genetic profile as 
isolates from aquatic insects and the clinical isolates obtained in the same region, as well 
as clinical isolates from other areas of West-Africa and different from isolates from some 
other regions (41). These observations implicate aquatic plants and insects as a reservoir 
of M. ulcerans. Nevertheless, the study could not differentiate between the African 
isolates, and the sample size was small. In our VNTR study we increased the sample size 
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and were able to find variants in isolates not only within Ghana, but within individual 
endemic districts.  The identification of differences in genotypes in the two main endemic 
districts of Ghana will enable studies to be made comparing these clinical isolates with 
environmental isolates from different areas.  
9.1.4 Immune response against M. ulcerans and the potential for vaccine development 
The treatment of BU with antibiotics or surgery is associated with a number of problems. 
The development of other preventive and control strategies, is therefore an important 
research priority. Institution of concrete preventive measures for acquiring infection is 
difficult without a clear understanding of the mode of transmission of M. ulcerans (51). 
The only risk factor identified so far, working or playing close to rivers in endemic areas, 
(40,44,45) is difficult to eliminate since  rivers serve as the main source of water for 
domestic activities, including cooking, drinking and washing in rural endemic 
communities. Keeping away from the streams will be difficult for women and children 
who must daily fetch water from streams. In addition, most of the endemic rural dwellers 
are farmers who depend on the riverine environments for crop cultivation. Thus an 
effective vaccine that prevents infection and/or disease seems to represent one of the 
preferred options for controlling the upsurge in BU cases.  
 
Currently, no effective vaccine for BU is available but there are evidences of some 
degree of cross-reactive protection conferred by M. bovis BCG (BCG) against BU 
disease. Two different case-controlled studies conducted in endemic regions of Uganda 
demonstrated that vaccination with BCG confers protection against BU ranging between 
18-74% with an overall protection rate of 47% (52,53). Intra-dermal inoculation of 
unprotected individuals with BCG in an endemic focus offered an overall protection of 
47% and this protective efficacy wanes after a year. Furthermore, the vaccinated group 
and individuals who mounted a delayed-type hypersensitivity response to the M. 
tuberculosis protein lysate, tuberculin, of 4 mm or more in the skin had smaller BU 
lesions than those in unvaccinated group (52). Portaels et al reported that effective BCG 
vaccination at birth may protect children against the development of severe disseminated 
disease like osteomyelitis (53). Analysis of the immune mechanisms potentially 
mediating this cross-protection indicated that the immuno-dominant protein antigen 
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Ag85A of BCG is recognised by the cellular immune system of M. ulcerans-infected 
mice. Furthermore, vaccination of mice with plasmid DNA encoding Ag85A from BCG 
was effective in reducing the bacterial load of M. ulcerans in the footpad (54). The M. 
ulcerans homolog of Ag85A shared 84.1% amino acid sequence identity and 91% 
conserved residues with M. bovis BCG. These findings indicate that immune responses 
against common mycobacterial antigens present in the BCG vaccine may offer some 
protection against BU and M. tuberculosis. However, this protection is not long-lasting 
and complete and therefore BCG has probably failed to control the increasing numbers of 
BU cases in West and Central Africa. In Ghana, a retrospective study conducted in 
Amansie-West district showed that there was no difference in the prevalence of BU 
between BCG vaccinated and non-vaccinated persons (55).  
 
Similar to infections with M. tuberculosis, it seems only a proportion of individuals 
infected with M. ulcerans develop active BU disease (12). This idea was corroborated by 
our analysis of serum concentrations of type 1 and type 2 cytokines in BU patients, 
household contacts and non-exposed controls, which indicated immune activation in both 
BU patients and their household contacts but not in the non-exposed controls by M. 
ulcerans (chapter 9).  Some BU patients also show spontaneous healing associated with 
the formation of granulomatous lesions and the development of delayed type 
hypersensitivity responses in burulin skin tests. These observations show that the 
induction of immunity to BU through vaccination is possible.  
 
Understanding the potentially protective or harmful immune mechanisms induced or 
suppressed during natural infection with M. ulcerans will support the rational design of 
vaccine against BU. Current knowledge of the mechanisms involved in protective 
immune response to M. ulcerans is limited. It appears that adaptive immune responses 
associated with IFN-γ secretion may be protective as individuals with defective receptors 
for INF-γ are highly susceptible to severe mycobacterial diseases including BU. Persons 
with past or current M. ulcerans disease had reduced INF-γ production in response to 
PPD of M. tuberculosis and M. bovis or whole killed M. bovis BCG or M. ulcerans 
compared to tuberculin positive individuals in endemic areas (56-58). We showed that 
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consistently with these reports, an ex vivo ELISpot analysis of PBMC revealed that the 
frequencies of systemic INF-γ producing cells after stimulation with IPP or PPD was 
significantly reduced in BU patients compared to healthy controls. This depressed INF-γ 
production was not restricted to immune responses specific for mycobacterial antigens 
but extended to CD4 T cell responses specific for influenza virus (chapter 7).  
 
In the study of Gooding et al, suppression of INF-γ production was not limited to subjects 
with active disease, but occurred in individuals with healed BU lesions (56). The authors 
suggested that individuals with BU may have genetic defects in the IFN-γ pathway 
predisposing for development of clinical disease. We analysed PBMC from the same 
patients before surgery and after healing in parallel by ELISpot analysis, and showed that 
the numbers of INF-γ secreting cells after antigen stimulation increased significantly after 
surgical treatment. By this finding we demonstrated for the first time that antigen-specific 
INF-γ production in BU patients is restored after healing. Therefore, individuals with BU 
do not seem to have genetic defects resulting in impaired INF-γ production since the 
observed suppression in T cell function was closely associated with infection with M. 
ulcerans. It would be of interest to investigate whether the recommended eight weeks of 
drug treatment in BU also leads to an improvement of the disease associated IFN-γ 
suppression as has been described in M. tuberculosis infections (59).  
 
IL-12 induces T and NK cells to produce several cytokines, including INF-γ (60). We 
observed that total IL-12 concentrations in culture supernatants of PPD stimulated PBMC 
were statistically higher in BU patients (treated and untreated) than in the controls 
(chapter 7). Therefore observed reduction in systemic INF-γ responses does not seem to 
be a consequence of diminished IL-12 production of the innate immune system. Studies 
of Prevot and Gooding suggested that Th2 mediated down-regulation of Th1 response 
may be involved in the reduced IFN-γ production observed in BU. In the study of Prevot, 
less extensive lesions (nodules) were associated with higher INF-γ and lower IL-10 
production and ulcerative lesions with lower INF-γ and higher IL-10 production (58). 
However, it is currently completely unknown what causes this unfavourable balance 
between IL-10 and INF-γ in mycobacterial diseases. It is a general belief that 
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mycolactone produced by M. ulcerans is the main virulence factor responsible for the 
observed immunosuppression in BU.  Interestingly, M. tuberculosis and M. ulcerans 
infections seem to share some impact on the host immune responses with BU. In both 
cases, infection leads to suppression in host systemic Th1 response (56,61) which 
resolves after treatment (59,62). In addition, immune protection by the BCG vaccine is 
also short lived, and seems to be more effective in controlling systemic infections than 
infection at tissue sites (63-65). At the time of diagnosis, our analysis of systemic 
production of IFN-γ after antigen stimulation was suppressed in both disease states but 
reverses after treatment. Restoration of T cell reactivity was slow such that an optimum 
response was not yet achieved by two months in both populations (chapter 8). 
The present PhD study could not analyse the variations in the composition of different 
cell subpopulations in the peripheral blood. It is recommended that future studies should 
look into this as it can be useful in explaining the underlying mechanisms involved in the 
observed reduced IFN-γ responses.   
 
From the above discussions, it appears that an effective vaccine for BU should prime an 
individual to mount a strong cellular Th1 response so as to enhance his ability to control 
initial inoculation. On the other hand, the induction of a neutralising antibody against the 
polyketide toxin, mycolactone, an essential virulence factor, should in essence disarm the 
pathogen and prevent it from causing disease. This strategy has been effectively used in 
the design of successful vaccines for the control of diseases including tetanus and 
diphtheria (66). Such a strategy will only be effective if the toxin will be highly 
immunogenic and can be neutralised by specific antibody responses. Mycolactone which 
has a polyketide structure may be on its own not an ideal structure and future research 
needs to look at the possibility of coupling neutralizing determinants of the toxin to 
suitable delivery systems for elucidating high titres of neutralizing antibody responses. 
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9.2 Conclusions 
 
This PhD work was conducted partly in Ghana where closeness to a BU endemic region 
was a major advantage. Several research stays at the Swiss Tropical Institute in Basel 
made certain types of laboratory analysis possible and facilitated technology transfer to 
the laboratories of the Noguchi Memorial Research Institute in Ghana. The most 
important scientific achievements are: 
 
1. A highly sensitive culturing system was established in an endemic country which 
enabled us to establish a large collection of M. ulcerans isolates from different 
endemic districts in Ghana, which were later used in analysing the diversity of M. 
ulcerans isolates. 
2. A simple in-expensive but rapid method for analysing the antimycobacterial 
sensitivity pattern was adapted for use in M. ulcerans. Screening of Ghanaian M. 
ulcerans isolates with this method for sensitivity to some drugs identified 
streptomycin and rifampicin resistant strains. This raises major concerns within 
the context of WHO’s recommendations for drug treatment of BU 
3. PCR, ZN staining and the established cultivation method were used to validate 
clinical diagnosis of patients reporting to the Amasaman Health Centre. Results 
demonstrated that clinical diagnosis performed by an experienced clinician can be 
very accurate, for both pre-ulcerative and ulcerative lesions.  
4. DNA fingerprinting of M. ulcerans isolates from Ghana by VNTR typing 
identified for the first time different genotypes within an endemic country of 
Africa. The most dominant African genotype was rarely found in Ghana and there 
seems to be an ongoing microevolution of M. ulcerans and spreading of new 
variants within Ghana  
5. The measurement of immediate IFN-γ secretion by ELISpot assay demonstrated 
that immuno-suppression in BU is not limited to mycobacterial antigens and that 
susceptibility to BU may not necessarily be due to genetic defects in IFN-γ as 
immuno-suppression was not permanent but reversed after removal of 
mycobacterial burden by surgical excision of the BU lesion.  
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6. Analysis of samples collected at different time points revealed that the reversal of 
immune suppressions in BU is slow and that mycolactone independent activities 
may be involved. 
7. The serum concentration of INF-γ, TNF-α, IL-4 and IL-6 was assessed in Buruli 
ulcer patients (BU), household contacts (HC) and non-exposed controls (NC). Our 
results demonstrate that about 75 % of BU and HC have enhanced INF-γ and 
TNF-α serum levels compared to NC indicative for immune activation by M. 
ulcerans exposure. 
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Abstract 
Interferon-gamma (IFN-γ) release after stimulation of peripheral blood mononuclear cells 
with specific antigens was analyzed in Buruli ulcer and tuberculosis patients undergoing 
treatment. Recovery of antigen-specific INF-γ production was quantified up to 2 months 
during treatment. Our result indicates that Mycobacterium ulcerans and M. tuberculosis 
infections cause long-lasting functional impairment of IFN-γ secretions. 
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Buruli ulcer (BU), caused by Mycobacterium ulcerans (M. ulcerans) infections, is the 
third most common mycobacterial disease in immuno-competent people, after 
tuberculosis and leprosy (14). Clinically, BU presents in the skin as chronic disease with 
either non-ulcerative (papules, nodules, plaques and edematous forms) or ulcerative 
lesions (7). Histo-pathological findings suggest that cell-mediated immunity plays a role 
in healing of BU. This is supported by the finding that delayed type hypersensitivity 
response to crude preparations of M. ulcerans (Burulin) was observed primarily in BU 
patients with healed or active disease (9). However, the involvement of the different 
components of the cellular immune system in protection is currently unclear. While the 
vast majority of mature T lymphocytes carry a T cell receptor (TCR) molecule composed 
of α and β chains, 1 – 5 % of circulating T cells express the γδ TCR hetero-dimer (3). T 
cells expressing the Vγ2Vδ2 TCR can account for up to 95 % of the γδ T cells in 
peripheral blood (3). After activation they secrete interferon-γ (INF-γ) and show 
cytotoxic T lymphocyte and natural killer cell-like effector functions (12,16). IPP 
represents a small phospho-antigen recognized exclusively by Vγ2Vδ2T cells and is 
produced during the largely prokaryotic non-mevalonate pathway of isoprenoid synthesis. 
It is assumed that Vγ2Vδ2T T cells sense proliferating pathogens that secrete very low 
amounts of intermediates of the non-mevalonate isoprenoid biosynthesis pathway 
providing a link between innate and adaptive immunity to a wide range of pathogens 
(2,8).  
 
From studies in M. tuberculosis it is known that chronically active pulmonary 
tuberculosis appears to down-regulate Vγ2Vδ2T T cell responses resulting in impaired 
cytokine production or proliferation to in vitro stimulation with phospho-antigens (10). 
We and others have shown that BU patients show impaired INF-γ production after 
stimulation of PBMC with live or dead mycobacteria, PPD, isopentenyl pyrophosphate 
and also to non-mycobacterial antigens (6,17,19). Several months after surgical excision 
of BU lesions, INF-γ responses against all antigens used for stimulation recovered 
significantly, indicating that the measured systemic immuno-suppression was not the 
consequence of a genetic defect predisposing for BU but is rather related to the presence 
of M. ulcerans bacteria (19). In the current study we extended and refined our previous 
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results in a group of BU patients by analysing the rate and pace of changes in INF-γ 
production after surgical removal of the BU lesions and compared to TB patients 
undergoing drug treatment.    
 
Seven TB and seven BU patients were involved in this study. The age range and clinical 
presentations for the BU and TB patients are indicated in tables 1 and 2 respectively. The 
BU patients were confirmed microbiologically by one of the following methods: IS2404 
PCR, culture and direct smear microscopy (18). The diagnosis of clinical TB was made 
on the medical history, physical examination and two acid-fast bacilli smear positive 
sputum samples according to the guidelines of the Ghana national tuberculosis program. 
The TB patients are new and had not received any therapy at the onset of the study. The 
first blood samples were collected from all patients before treatment. BU patients were all 
treated by surgical excision and TB patients by chemotherapy. For BU patients second 
and third blood samples were collected later after one and two months respectively. A 
second sample was collected two months later from the TB patients after being treated by 
DOTS with rifampicin/isoniazid/streptomycin and have converted to sputum smear 
negative.  Peripheral blood mononuclear cells (PBMC) were separated within four hours 
after drawing peripheral venous blood, cryo preserved in Ghana and transported on liquid 
nitrogen to Basel for further analysis. This study was approved by the Institutional 
Review Board of the Noguchi Memorial Institute for Medical Research, and informed 
consent was obtained from the all subjects or their parents. The ex vivo ELISpot analysis 
was conducted essentially as described (19). The antigens used for stimulation of PBMC 
included, isopentenyl pyrophosphate (IPP) described as main stimulatory for Vγ2Vδ2 
lymphocytes , PPD of M. tuberculosis that is stimulatory for CD4+ and Vγ2Vδ2 T cell 
subset  and mitogen PHA. Spots were counted by the ELISpot Reader system (AID, 
Germany). Antigen-specific cells per 106 PBMC were calculated by subtracting spot 
numbers in media control wells from spot numbers in antigen-containing wells. Data 
were analyzed using the STATA program (Stata Corporation). Data was considered 
significant when P< 0.05. 
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In Figure 1, the SFU for each individual patient during the longitudinal study are given.  
After stimulation with PHA, all BU patients showed considerable INF-γ secretion. 
Hence, BU patients were able to respond to mitogen stimulation with INF-γ secretion 
with responses remaining stable over the time points analyzed. Therefore, a general 
immuno-suppression of INF-γ production and variations in quality of PBMC sample 
cryo-preservation could be excluded (Figure 1). In contrast, in four BU patients, the IPP 
induced INF-γ secretion increased significantly two months after surgery. Three patients 
remained at the same level during the course of investigation (Figure 1). Two out of these 
four patients showed also improvement of INF-γ secretion in PPD stimulated PBMC 
(Figure 1). As shown in figure 2, only two of the seven TB patients had a significant 
increase in IFN- γ secretion in response to IPP stimulation, and one had a marginal 
increase within two months of treatment. Two of these three patients together with three 
other patients improved significantly in IFN- γ secretion upon PPD stimulation of their 
PBMC. Contrary to the BU patients, there was a difference in response to PHA between 
before and during treatment (p=0.01). This finding agrees with previous findings, that T 
cell anergy in advanced TB patients extends to mitogens (4,15). As indicated in table 2 
most of the TB patients were advanced smear positive cases. 
 
In light of previous studies suggesting Vγ2Vδ2 T cell dysfunction in M. tuberculosis and 
HIV infections, which improves upon effective drug treatment (1,11), we investigated 
changes in immediate effector function in a group of BU and TB patients undergoing 
surgical and drug treatment. Our result indicates that, even though antigen induced 
cytokine secretion improved in some of the patients (in both groups) two months within 
treatment, the mean response was still low compared to healthy Ghanaian controls (19), 
especially after IRIV stimulation (result not shown). We thus confirmed that in M. 
tuberculosis and M. ulcerans infections, after appropriate treatment regimens, cellular 
immune responses improved significantly which might be indicative for shared immuno-
pathogenic mechanisms of mycobacteria. Given the slow recovery of INF-γ secretion 
after surgery, our results question the idea that the toxin mycolactone produced by M. 
ulcerans presents the only virulence factor of M. ulcerans (5).  
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Currently, the exact mode of transmission and the reservoirs involved in BU remains to 
be determined (13). Additionally, it is presently unclear what proportions of people that 
have contact with the pathogen develop actually the clinical disease. In future, population 
based studies would help to define the stage of M. ulcerans exposure and/or infection that 
results in suppression of immediate effector function of Vγ2Vδ2T cells. Additionally, it 
would be of interest to follow BU patients without improvement of INF-γ production 
after surgical treatment in terms of recurrence and/or super-infection with M. ulcerans. In 
summary, previous observations of with systemic immuno-suppression of Vγ2Vδ2 T cell 
effector function that resolves gradually after surgical removal of bacteria are confirmed 
and refined. 
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patient 
 
age 
 
gender 
 
clinical 
form a 
 
BCG 
status b 
 
AFB 
c
 
 
Culture 
d
 
 
PCR 
e
 
 
1st 
sample f 
 
2nd 
sample f 
 
3rd 
sample f 
P23 10 f ulcerative + + + + 0 1 mo 2 mo 
P26 16 f ulcerative ND + + + 0 1 mo 2 mo 
P27 16 m nodule ND - + _ 0 1 mo 2 mo 
P28 4.5 m ulcerative + + + + 0 1 mo 2 mo 
P29 3.5 f ulcerative + + + + 0 1 mo 2 mo 
P30 4 m nodule + + + + 0 1 mo 2 mo 
P31 5 f ulcerative + - - + 0 1 mo 2 mo 
P32 3 m ulcerative + + + + 0 1 mo 2 mo 
P34 40 f ulcerative + + + + 0 1 mo 2 mo 
Table I: Clinical data of patients presenting with lesions due to confirmed M. ulcerans 
infection 
a clinical forms of BU disease were graded according to the WHO case definition . 
b
 BCG status was determined by confirmation of the presence of a BCG scar by two 
persons. 
c
 Acid fast bacilli detection was performed by direct smearing of tissue exudates followed 
by Ziehl Neelson staining . d Culture of M. ulcerans according to . e IS2404 PCR analysis 
according to . f Time of blood sample collection. Time 0 is time of surgical treatment 
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patient 
 
age 
 
gender 
 
clinical forma 
 
BCG 
statusb 
 
AFBc 
 
1st blood 
sample f 
 
2nd blood 
sample f 
TB01 21 M Pulmonary + + 0 2 mo 
TB02 38 M Pulmonary nd + 0 2 mo 
TB05 30 F Pulmonary nd ++ 0 2 mo 
TB06 21 M Pulmonary + + 0 2 mo 
TB09 35 M Pulmonary - +++ 0 2 mo 
TB10 24 F Pulmonary + ++ 0 2 mo 
TB12 36 M Pulmonary - +++ 0 2 mo 
 
Table II: Clinical data of patients presenting with lesions due to confirmed tuberculosis 
infection 
b
 BCG status was determined by confirmation of the presence of a BCG scar by two 
persons. 
c
 Acid fast bacilli detection was performed by direct smearing of tissue exudates followed 
by Ziehl Neelson staining . 
f
 Time of blood sample collection. Time 0 is time of diagnosis before treatment  
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Figure 1: Increase in antigen-specific ex vivo INF-γ secreting cells in BU patients 
after surgical treatment. PBMC of seven BU patients sampled at day 0, 30 and 60 
post surgery (p.s.) (Table I) were thawed into cell culture medium and kept overnight 
in the presence or absence of IPP (a), PPD (b) and PHA (c).  
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Figure 2: Increase of antigen-specific ex vivo INF-γ secretion in TB patients during 
treatment. PBMC of seven TB patients sampled at day 0, and 60 of treatment (Table 
2) were thawed into cell culture medium and kept overnight in the presence or 
absence of IPP (a), PPD (b) and PHA (c).  
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